CINXE.COM

<!DOCTYPE html> <html class="client-nojs vector-feature-language-in-header-enabled vector-feature-language-in-main-page-header-disabled vector-feature-sticky-header-disabled vector-feature-page-tools-pinned-disabled vector-feature-toc-pinned-clientpref-1 vector-feature-main-menu-pinned-disabled vector-feature-limited-width-clientpref-1 vector-feature-limited-width-content-enabled vector-feature-custom-font-size-clientpref-1 vector-feature-appearance-pinned-clientpref-1 vector-feature-night-mode-enabled skin-theme-clientpref-day vector-toc-available" lang="en" dir="ltr"> <head> <meta charset="UTF-8"> <title>Inavolisib - Wikipedia</title> <script>(function(){var className="client-js vector-feature-language-in-header-enabled vector-feature-language-in-main-page-header-disabled vector-feature-sticky-header-disabled vector-feature-page-tools-pinned-disabled vector-feature-toc-pinned-clientpref-1 vector-feature-main-menu-pinned-disabled vector-feature-limited-width-clientpref-1 vector-feature-limited-width-content-enabled vector-feature-custom-font-size-clientpref-1 vector-feature-appearance-pinned-clientpref-1 vector-feature-night-mode-enabled skin-theme-clientpref-day vector-toc-available";var cookie=document.cookie.match(/(?:^|; )enwikimwclientpreferences=([^;]+)/);if(cookie){cookie[1].split('%2C').forEach(function(pref){className=className.replace(new RegExp('(^| )'+pref.replace(/-clientpref-\w+$|[^\w-]+/g,'')+'-clientpref-\\w+( |$)'),'$1'+pref+'$2');});}document.documentElement.className=className;}());RLCONF={"wgBreakFrames":false,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy", "wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"a97815aa-99bb-490c-99bd-c006cff54a4b","wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Inavolisib","wgTitle":"Inavolisib","wgCurRevisionId":1260343068,"wgRevisionId":1260343068,"wgArticleId":73327105,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Source attribution","Articles with short description","Short description matches Wikidata","Use dmy dates from November 2024","Articles containing unverified chemical infoboxes","All articles lacking reliable references","Articles lacking reliable references from October 2024","Drugs not assigned an ATC code","Antineoplastic drugs","Phosphoinositide 3-kinase inhibitors","Acetamides","Benzoxazepines","Difluoromethyl compounds","Oxazolidinones","Drugs developed by Genentech", "Drugs developed by Hoffmann-La Roche"],"wgPageViewLanguage":"en","wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Inavolisib","wgRelevantArticleId":73327105,"wgIsProbablyEditable":true,"wgRelevantPageIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgNoticeProject":"wikipedia","wgCiteReferencePreviewsActive":false,"wgFlaggedRevsParams":{"tags":{"status":{"levels":1}}},"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wgPopupsFlags":0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"wgMFDisplayWikibaseDescriptions":{"search":true,"watchlist":true,"tagline":false,"nearby":true},"wgWMESchemaEditAttemptStepOversample":false,"wgWMEPageLength":20000,"wgRelatedArticlesCompat":[],"wgEditSubmitButtonLabelPublish":true,"wgULSPosition":"interlanguage","wgULSisCompactLinksEnabled":false,"wgVector2022LanguageInHeader":true,"wgULSisLanguageSelectorEmpty":false,"wgWikibaseItemId": "Q122766610","wgCheckUserClientHintsHeadersJsApi":["brands","architecture","bitness","fullVersionList","mobile","model","platform","platformVersion"],"GEHomepageSuggestedEditsEnableTopics":true,"wgGETopicsMatchModeEnabled":false,"wgGEStructuredTaskRejectionReasonTextInputEnabled":false,"wgGELevelingUpEnabledForUser":false};RLSTATE={"ext.globalCssJs.user.styles":"ready","site.styles":"ready","user.styles":"ready","ext.globalCssJs.user":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","skins.vector.search.codex.styles":"ready","skins.vector.styles":"ready","skins.vector.icons":"ready","jquery.makeCollapsible.styles":"ready","ext.wikimediamessages.styles":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.uls.interlanguage":"ready","wikibase.client.init":"ready","ext.wikimediaBadges":"ready"};RLPAGEMODULES=["ext.cite.ux-enhancements","site","mediawiki.page.ready","jquery.makeCollapsible","mediawiki.toc","skins.vector.js", "ext.centralNotice.geoIP","ext.centralNotice.startUp","ext.gadget.ReferenceTooltips","ext.gadget.switcher","ext.urlShortener.toolbar","ext.centralauth.centralautologin","mmv.bootstrap","ext.popups","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.echo.centralauth","ext.eventLogging","ext.wikimediaEvents","ext.navigationTiming","ext.uls.interface","ext.cx.eventlogging.campaigns","ext.cx.uls.quick.actions","wikibase.client.vector-2022","ext.checkUser.clientHints","ext.growthExperiments.SuggestedEditSession","wikibase.sidebar.tracking"];</script> <script>(RLQ=window.RLQ||[]).push(function(){mw.loader.impl(function(){return["user.options@12s5i",function($,jQuery,require,module){mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"}); }];});});</script> <link rel="stylesheet" href="/w/load.php?lang=en&modules=ext.cite.styles%7Cext.uls.interlanguage%7Cext.visualEditor.desktopArticleTarget.noscript%7Cext.wikimediaBadges%7Cext.wikimediamessages.styles%7Cjquery.makeCollapsible.styles%7Cskins.vector.icons%2Cstyles%7Cskins.vector.search.codex.styles%7Cwikibase.client.init&only=styles&skin=vector-2022"> <script async="" src="/w/load.php?lang=en&modules=startup&only=scripts&raw=1&skin=vector-2022"></script> <meta name="ResourceLoaderDynamicStyles" content=""> <link rel="stylesheet" href="/w/load.php?lang=en&modules=site.styles&only=styles&skin=vector-2022"> <meta name="generator" content="MediaWiki 1.44.0-wmf.5"> <meta name="referrer" content="origin"> <meta name="referrer" content="origin-when-cross-origin"> <meta name="robots" content="max-image-preview:standard"> <meta name="format-detection" content="telephone=no"> <meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/2/28/Inavolisib.svg/1200px-Inavolisib.svg.png"> <meta property="og:image:width" content="1200"> <meta property="og:image:height" content="571"> <meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/2/28/Inavolisib.svg/800px-Inavolisib.svg.png"> <meta property="og:image:width" content="800"> <meta property="og:image:height" content="381"> <meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/2/28/Inavolisib.svg/640px-Inavolisib.svg.png"> <meta property="og:image:width" content="640"> <meta property="og:image:height" content="305"> <meta name="viewport" content="width=1120"> <meta property="og:title" content="Inavolisib - Wikipedia"> <meta property="og:type" content="website"> <link rel="preconnect" href="//upload.wikimedia.org"> <link rel="alternate" media="only screen and (max-width: 640px)" href="//en.m.wikipedia.org/wiki/Inavolisib"> <link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Inavolisib&action=edit"> <link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"> <link rel="icon" href="/static/favicon/wikipedia.ico"> <link rel="search" type="application/opensearchdescription+xml" href="/w/rest.php/v1/search" title="Wikipedia (en)"> <link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"> <link rel="canonical" href="https://en.wikipedia.org/wiki/Inavolisib"> <link rel="license" href="https://creativecommons.org/licenses/by-sa/4.0/deed.en"> <link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&feed=atom"> <link rel="dns-prefetch" href="//meta.wikimedia.org" /> <link rel="dns-prefetch" href="//login.wikimedia.org"> </head> <body class="skin--responsive skin-vector skin-vector-search-vue mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-Inavolisib rootpage-Inavolisib skin-vector-2022 action-view"><a class="mw-jump-link" href="#bodyContent">Jump to content</a> <div class="vector-header-container"> <header class="vector-header mw-header"> <div class="vector-header-start"> <nav class="vector-main-menu-landmark" aria-label="Site"> <div id="vector-main-menu-dropdown" class="vector-dropdown vector-main-menu-dropdown vector-button-flush-left vector-button-flush-right" > <input type="checkbox" id="vector-main-menu-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-main-menu-dropdown" class="vector-dropdown-checkbox " aria-label="Main menu" > <label id="vector-main-menu-dropdown-label" for="vector-main-menu-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-menu mw-ui-icon-wikimedia-menu"></span> <span class="vector-dropdown-label-text">Main menu</span> </label> <div class="vector-dropdown-content"> <div id="vector-main-menu-unpinned-container" class="vector-unpinned-container"> <div id="vector-main-menu" class="vector-main-menu vector-pinnable-element"> <div class="vector-pinnable-header vector-main-menu-pinnable-header vector-pinnable-header-unpinned" data-feature-name="main-menu-pinned" data-pinnable-element-id="vector-main-menu" data-pinned-container-id="vector-main-menu-pinned-container" data-unpinned-container-id="vector-main-menu-unpinned-container" > <div class="vector-pinnable-header-label">Main menu</div> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-main-menu.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-main-menu.unpin">hide</button> </div> <div id="p-navigation" class="vector-menu mw-portlet mw-portlet-navigation" > <div class="vector-menu-heading"> Navigation </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="n-mainpage-description" class="mw-list-item"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z"><span>Main page</span></a></li><li id="n-contents" class="mw-list-item"><a href="/wiki/Wikipedia:Contents" title="Guides to browsing Wikipedia"><span>Contents</span></a></li><li id="n-currentevents" class="mw-list-item"><a href="/wiki/Portal:Current_events" title="Articles related to current events"><span>Current events</span></a></li><li id="n-randompage" class="mw-list-item"><a href="/wiki/Special:Random" title="Visit a randomly selected article [x]" accesskey="x"><span>Random article</span></a></li><li id="n-aboutsite" class="mw-list-item"><a href="/wiki/Wikipedia:About" title="Learn about Wikipedia and how it works"><span>About Wikipedia</span></a></li><li id="n-contactpage" class="mw-list-item"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia"><span>Contact us</span></a></li> </ul> </div> </div> <div id="p-interaction" class="vector-menu mw-portlet mw-portlet-interaction" > <div class="vector-menu-heading"> Contribute </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="n-help" class="mw-list-item"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia"><span>Help</span></a></li><li id="n-introduction" class="mw-list-item"><a href="/wiki/Help:Introduction" title="Learn how to edit Wikipedia"><span>Learn to edit</span></a></li><li id="n-portal" class="mw-list-item"><a href="/wiki/Wikipedia:Community_portal" title="The hub for editors"><span>Community portal</span></a></li><li id="n-recentchanges" class="mw-list-item"><a href="/wiki/Special:RecentChanges" title="A list of recent changes to Wikipedia [r]" accesskey="r"><span>Recent changes</span></a></li><li id="n-upload" class="mw-list-item"><a href="/wiki/Wikipedia:File_upload_wizard" title="Add images or other media for use on Wikipedia"><span>Upload file</span></a></li> </ul> </div> </div> </div> </div> </div> </div> </nav> <a href="/wiki/Main_Page" class="mw-logo"> <img class="mw-logo-icon" src="/static/images/icons/wikipedia.png" alt="" aria-hidden="true" height="50" width="50"> <span class="mw-logo-container skin-invert"> <img class="mw-logo-wordmark" alt="Wikipedia" src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" style="width: 7.5em; height: 1.125em;"> <img class="mw-logo-tagline" alt="The Free Encyclopedia" src="/static/images/mobile/copyright/wikipedia-tagline-en.svg" width="117" height="13" style="width: 7.3125em; height: 0.8125em;"> </span> </a> </div> <div class="vector-header-end"> <div id="p-search" role="search" class="vector-search-box-vue vector-search-box-collapses vector-search-box-show-thumbnail vector-search-box-auto-expand-width vector-search-box"> <a href="/wiki/Special:Search" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only search-toggle" title="Search Wikipedia [f]" accesskey="f"><span class="vector-icon mw-ui-icon-search mw-ui-icon-wikimedia-search"></span> <span>Search</span> </a> <div class="vector-typeahead-search-container"> <div class="cdx-typeahead-search cdx-typeahead-search--show-thumbnail cdx-typeahead-search--auto-expand-width"> <form action="/w/index.php" id="searchform" class="cdx-search-input cdx-search-input--has-end-button"> <div id="simpleSearch" class="cdx-search-input__input-wrapper" data-search-loc="header-moved"> <div class="cdx-text-input cdx-text-input--has-start-icon"> <input class="cdx-text-input__input" type="search" name="search" placeholder="Search Wikipedia" aria-label="Search Wikipedia" autocapitalize="sentences" title="Search Wikipedia [f]" accesskey="f" id="searchInput" > <span class="cdx-text-input__icon cdx-text-input__start-icon"></span> </div> <input type="hidden" name="title" value="Special:Search"> </div> <button class="cdx-button cdx-search-input__end-button">Search</button> </form> </div> </div> </div> <nav class="vector-user-links vector-user-links-wide" aria-label="Personal tools"> <div class="vector-user-links-main"> <div id="p-vector-user-menu-preferences" class="vector-menu mw-portlet emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> <div id="p-vector-user-menu-userpage" class="vector-menu mw-portlet emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> <nav class="vector-appearance-landmark" aria-label="Appearance"> <div id="vector-appearance-dropdown" class="vector-dropdown " title="Change the appearance of the page's font size, width, and color" > <input type="checkbox" id="vector-appearance-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-appearance-dropdown" class="vector-dropdown-checkbox " aria-label="Appearance" > <label id="vector-appearance-dropdown-label" for="vector-appearance-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-appearance mw-ui-icon-wikimedia-appearance"></span> <span class="vector-dropdown-label-text">Appearance</span> </label> <div class="vector-dropdown-content"> <div id="vector-appearance-unpinned-container" class="vector-unpinned-container"> </div> </div> </div> </nav> <div id="p-vector-user-menu-notifications" class="vector-menu mw-portlet emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> <div id="p-vector-user-menu-overflow" class="vector-menu mw-portlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="pt-sitesupport-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en" class=""><span>Donate</span></a> </li> <li id="pt-createaccount-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="/w/index.php?title=Special:CreateAccount&returnto=Inavolisib" title="You are encouraged to create an account and log in; however, it is not mandatory" class=""><span>Create account</span></a> </li> <li id="pt-login-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="/w/index.php?title=Special:UserLogin&returnto=Inavolisib" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o" class=""><span>Log in</span></a> </li> </ul> </div> </div> </div> <div id="vector-user-links-dropdown" class="vector-dropdown vector-user-menu vector-button-flush-right vector-user-menu-logged-out" title="Log in and more options" > <input type="checkbox" id="vector-user-links-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-user-links-dropdown" class="vector-dropdown-checkbox " aria-label="Personal tools" > <label id="vector-user-links-dropdown-label" for="vector-user-links-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-ellipsis mw-ui-icon-wikimedia-ellipsis"></span> <span class="vector-dropdown-label-text">Personal tools</span> </label> <div class="vector-dropdown-content"> <div id="p-personal" class="vector-menu mw-portlet mw-portlet-personal user-links-collapsible-item" title="User menu" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="pt-sitesupport" class="user-links-collapsible-item mw-list-item"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en"><span>Donate</span></a></li><li id="pt-createaccount" class="user-links-collapsible-item mw-list-item"><a href="/w/index.php?title=Special:CreateAccount&returnto=Inavolisib" title="You are encouraged to create an account and log in; however, it is not mandatory"><span class="vector-icon mw-ui-icon-userAdd mw-ui-icon-wikimedia-userAdd"></span> <span>Create account</span></a></li><li id="pt-login" class="user-links-collapsible-item mw-list-item"><a href="/w/index.php?title=Special:UserLogin&returnto=Inavolisib" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o"><span class="vector-icon mw-ui-icon-logIn mw-ui-icon-wikimedia-logIn"></span> <span>Log in</span></a></li> </ul> </div> </div> <div id="p-user-menu-anon-editor" class="vector-menu mw-portlet mw-portlet-user-menu-anon-editor" > <div class="vector-menu-heading"> Pages for logged out editors <a href="/wiki/Help:Introduction" aria-label="Learn more about editing"><span>learn more</span></a> </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="pt-anoncontribs" class="mw-list-item"><a href="/wiki/Special:MyContributions" title="A list of edits made from this IP address [y]" accesskey="y"><span>Contributions</span></a></li><li id="pt-anontalk" class="mw-list-item"><a href="/wiki/Special:MyTalk" title="Discussion about edits from this IP address [n]" accesskey="n"><span>Talk</span></a></li> </ul> </div> </div> </div> </div> </nav> </div> </header> </div> <div class="mw-page-container"> <div class="mw-page-container-inner"> <div class="vector-sitenotice-container"> <div id="siteNotice"></div> </div> <div class="vector-column-start"> <div class="vector-main-menu-container"> <div id="mw-navigation"> <nav id="mw-panel" class="vector-main-menu-landmark" aria-label="Site"> <div id="vector-main-menu-pinned-container" class="vector-pinned-container"> </div> </nav> </div> </div> <div class="vector-sticky-pinned-container"> <nav id="mw-panel-toc" aria-label="Contents" data-event-name="ui.sidebar-toc" class="mw-table-of-contents-container vector-toc-landmark"> <div id="vector-toc-pinned-container" class="vector-pinned-container"> <div id="vector-toc" class="vector-toc vector-pinnable-element"> <div class="vector-pinnable-header vector-toc-pinnable-header vector-pinnable-header-pinned" data-feature-name="toc-pinned" data-pinnable-element-id="vector-toc" > <h2 class="vector-pinnable-header-label">Contents</h2> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-toc.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-toc.unpin">hide</button> </div> <ul class="vector-toc-contents" id="mw-panel-toc-list"> <li id="toc-mw-content-text" class="vector-toc-list-item vector-toc-level-1"> <a href="#" class="vector-toc-link"> <div class="vector-toc-text">(Top)</div> </a> </li> <li id="toc-Medical_uses" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Medical_uses"> <div class="vector-toc-text"> <span class="vector-toc-numb">1</span> <span>Medical uses</span> </div> </a> <ul id="toc-Medical_uses-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Side_effects" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Side_effects"> <div class="vector-toc-text"> <span class="vector-toc-numb">2</span> <span>Side effects</span> </div> </a> <ul id="toc-Side_effects-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-History" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#History"> <div class="vector-toc-text"> <span class="vector-toc-numb">3</span> <span>History</span> </div> </a> <ul id="toc-History-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Structure,_reactivity,_and_synthesis" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Structure,_reactivity,_and_synthesis"> <div class="vector-toc-text"> <span class="vector-toc-numb">4</span> <span>Structure, reactivity, and synthesis</span> </div> </a> <ul id="toc-Structure,_reactivity,_and_synthesis-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Metabolism_and_biotransformation" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Metabolism_and_biotransformation"> <div class="vector-toc-text"> <span class="vector-toc-numb">5</span> <span>Metabolism and biotransformation</span> </div> </a> <ul id="toc-Metabolism_and_biotransformation-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Molecular_mechanisms_of_action" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Molecular_mechanisms_of_action"> <div class="vector-toc-text"> <span class="vector-toc-numb">6</span> <span>Molecular mechanisms of action</span> </div> </a> <ul id="toc-Molecular_mechanisms_of_action-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Toxicity" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Toxicity"> <div class="vector-toc-text"> <span class="vector-toc-numb">7</span> <span>Toxicity</span> </div> </a> <ul id="toc-Toxicity-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Society_and_culture" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Society_and_culture"> <div class="vector-toc-text"> <span class="vector-toc-numb">8</span> <span>Society and culture</span> </div> </a> <button aria-controls="toc-Society_and_culture-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle"> <span class="vector-icon mw-ui-icon-wikimedia-expand"></span> <span>Toggle Society and culture subsection</span> </button> <ul id="toc-Society_and_culture-sublist" class="vector-toc-list"> <li id="toc-Legal_status" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Legal_status"> <div class="vector-toc-text"> <span class="vector-toc-numb">8.1</span> <span>Legal status</span> </div> </a> <ul id="toc-Legal_status-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Names" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Names"> <div class="vector-toc-text"> <span class="vector-toc-numb">8.2</span> <span>Names</span> </div> </a> <ul id="toc-Names-sublist" class="vector-toc-list"> </ul> </li> </ul> </li> <li id="toc-Research" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Research"> <div class="vector-toc-text"> <span class="vector-toc-numb">9</span> <span>Research</span> </div> </a> <ul id="toc-Research-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-References" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#References"> <div class="vector-toc-text"> <span class="vector-toc-numb">10</span> <span>References</span> </div> </a> <ul id="toc-References-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-External_links" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#External_links"> <div class="vector-toc-text"> <span class="vector-toc-numb">11</span> <span>External links</span> </div> </a> <ul id="toc-External_links-sublist" class="vector-toc-list"> </ul> </li> </ul> </div> </div> </nav> </div> </div> <div class="mw-content-container"> <main id="content" class="mw-body"> <header class="mw-body-header vector-page-titlebar"> <nav aria-label="Contents" class="vector-toc-landmark"> <div id="vector-page-titlebar-toc" class="vector-dropdown vector-page-titlebar-toc vector-button-flush-left" > <input type="checkbox" id="vector-page-titlebar-toc-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-page-titlebar-toc" class="vector-dropdown-checkbox " aria-label="Toggle the table of contents" > <label id="vector-page-titlebar-toc-label" for="vector-page-titlebar-toc-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-listBullet mw-ui-icon-wikimedia-listBullet"></span> <span class="vector-dropdown-label-text">Toggle the table of contents</span> </label> <div class="vector-dropdown-content"> <div id="vector-page-titlebar-toc-unpinned-container" class="vector-unpinned-container"> </div> </div> </div> </nav> <h1 id="firstHeading" class="firstHeading mw-first-heading"><span class="mw-page-title-main">Inavolisib</span></h1> <div id="p-lang-btn" class="vector-dropdown mw-portlet mw-portlet-lang" > <input type="checkbox" id="p-lang-btn-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-p-lang-btn" class="vector-dropdown-checkbox mw-interlanguage-selector" aria-label="Go to an article in another language. Available in 1 language" > <label id="p-lang-btn-label" for="p-lang-btn-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--action-progressive mw-portlet-lang-heading-1" aria-hidden="true" ><span class="vector-icon mw-ui-icon-language-progressive mw-ui-icon-wikimedia-language-progressive"></span> <span class="vector-dropdown-label-text">1 language</span> </label> <div class="vector-dropdown-content"> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li class="interlanguage-link interwiki-zh mw-list-item"><a href="https://zh.wikipedia.org/wiki/%E4%BC%8A%E7%BA%B3%E6%B2%83%E5%88%A9%E6%98%94%E5%B8%83" title="伊纳沃利昔布 – Chinese" lang="zh" hreflang="zh" data-title="伊纳沃利昔布" data-language-autonym="中文" data-language-local-name="Chinese" class="interlanguage-link-target"><span>中文</span></a></li> </ul> <div class="after-portlet after-portlet-lang"><span class="wb-langlinks-edit wb-langlinks-link"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q122766610#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div> </div> </div> </div> </header> <div class="vector-page-toolbar"> <div class="vector-page-toolbar-container"> <div id="left-navigation"> <nav aria-label="Namespaces"> <div id="p-associated-pages" class="vector-menu vector-menu-tabs mw-portlet mw-portlet-associated-pages" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="ca-nstab-main" class="selected vector-tab-noicon mw-list-item"><a href="/wiki/Inavolisib" title="View the content page [c]" accesskey="c"><span>Article</span></a></li><li id="ca-talk" class="vector-tab-noicon mw-list-item"><a href="/wiki/Talk:Inavolisib" rel="discussion" title="Discuss improvements to the content page [t]" accesskey="t"><span>Talk</span></a></li> </ul> </div> </div> <div id="vector-variants-dropdown" class="vector-dropdown emptyPortlet" > <input type="checkbox" id="vector-variants-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-variants-dropdown" class="vector-dropdown-checkbox " aria-label="Change language variant" > <label id="vector-variants-dropdown-label" for="vector-variants-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet" aria-hidden="true" ><span class="vector-dropdown-label-text">English</span> </label> <div class="vector-dropdown-content"> <div id="p-variants" class="vector-menu mw-portlet mw-portlet-variants emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> </div> </div> </nav> </div> <div id="right-navigation" class="vector-collapsible"> <nav aria-label="Views"> <div id="p-views" class="vector-menu vector-menu-tabs mw-portlet mw-portlet-views" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="ca-view" class="selected vector-tab-noicon mw-list-item"><a href="/wiki/Inavolisib"><span>Read</span></a></li><li id="ca-edit" class="vector-tab-noicon mw-list-item"><a href="/w/index.php?title=Inavolisib&action=edit" title="Edit this page [e]" accesskey="e"><span>Edit</span></a></li><li id="ca-history" class="vector-tab-noicon mw-list-item"><a href="/w/index.php?title=Inavolisib&action=history" title="Past revisions of this page [h]" accesskey="h"><span>View history</span></a></li> </ul> </div> </div> </nav> <nav class="vector-page-tools-landmark" aria-label="Page tools"> <div id="vector-page-tools-dropdown" class="vector-dropdown vector-page-tools-dropdown" > <input type="checkbox" id="vector-page-tools-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-page-tools-dropdown" class="vector-dropdown-checkbox " aria-label="Tools" > <label id="vector-page-tools-dropdown-label" for="vector-page-tools-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet" aria-hidden="true" ><span class="vector-dropdown-label-text">Tools</span> </label> <div class="vector-dropdown-content"> <div id="vector-page-tools-unpinned-container" class="vector-unpinned-container"> <div id="vector-page-tools" class="vector-page-tools vector-pinnable-element"> <div class="vector-pinnable-header vector-page-tools-pinnable-header vector-pinnable-header-unpinned" data-feature-name="page-tools-pinned" data-pinnable-element-id="vector-page-tools" data-pinned-container-id="vector-page-tools-pinned-container" data-unpinned-container-id="vector-page-tools-unpinned-container" > <div class="vector-pinnable-header-label">Tools</div> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-page-tools.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-page-tools.unpin">hide</button> </div> <div id="p-cactions" class="vector-menu mw-portlet mw-portlet-cactions emptyPortlet vector-has-collapsible-items" title="More options" > <div class="vector-menu-heading"> Actions </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="ca-more-view" class="selected vector-more-collapsible-item mw-list-item"><a href="/wiki/Inavolisib"><span>Read</span></a></li><li id="ca-more-edit" class="vector-more-collapsible-item mw-list-item"><a href="/w/index.php?title=Inavolisib&action=edit" title="Edit this page [e]" accesskey="e"><span>Edit</span></a></li><li id="ca-more-history" class="vector-more-collapsible-item mw-list-item"><a href="/w/index.php?title=Inavolisib&action=history"><span>View history</span></a></li> </ul> </div> </div> <div id="p-tb" class="vector-menu mw-portlet mw-portlet-tb" > <div class="vector-menu-heading"> General </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="t-whatlinkshere" class="mw-list-item"><a href="/wiki/Special:WhatLinksHere/Inavolisib" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j"><span>What links here</span></a></li><li id="t-recentchangeslinked" class="mw-list-item"><a href="/wiki/Special:RecentChangesLinked/Inavolisib" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k"><span>Related changes</span></a></li><li id="t-upload" class="mw-list-item"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u"><span>Upload file</span></a></li><li id="t-specialpages" class="mw-list-item"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q"><span>Special pages</span></a></li><li id="t-permalink" class="mw-list-item"><a href="/w/index.php?title=Inavolisib&oldid=1260343068" title="Permanent link to this revision of this page"><span>Permanent link</span></a></li><li id="t-info" class="mw-list-item"><a href="/w/index.php?title=Inavolisib&action=info" title="More information about this page"><span>Page information</span></a></li><li id="t-cite" class="mw-list-item"><a href="/w/index.php?title=Special:CiteThisPage&page=Inavolisib&id=1260343068&wpFormIdentifier=titleform" title="Information on how to cite this page"><span>Cite this page</span></a></li><li id="t-urlshortener" class="mw-list-item"><a href="/w/index.php?title=Special:UrlShortener&url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FInavolisib"><span>Get shortened URL</span></a></li><li id="t-urlshortener-qrcode" class="mw-list-item"><a href="/w/index.php?title=Special:QrCode&url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FInavolisib"><span>Download QR code</span></a></li> </ul> </div> </div> <div id="p-coll-print_export" class="vector-menu mw-portlet mw-portlet-coll-print_export" > <div class="vector-menu-heading"> Print/export </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="coll-download-as-rl" class="mw-list-item"><a href="/w/index.php?title=Special:DownloadAsPdf&page=Inavolisib&action=show-download-screen" title="Download this page as a PDF file"><span>Download as PDF</span></a></li><li id="t-print" class="mw-list-item"><a href="/w/index.php?title=Inavolisib&printable=yes" title="Printable version of this page [p]" accesskey="p"><span>Printable version</span></a></li> </ul> </div> </div> <div id="p-wikibase-otherprojects" class="vector-menu mw-portlet mw-portlet-wikibase-otherprojects" > <div class="vector-menu-heading"> In other projects </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="t-wikibase" class="wb-otherproject-link wb-otherproject-wikibase-dataitem mw-list-item"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q122766610" title="Structured data on this page hosted by Wikidata [g]" accesskey="g"><span>Wikidata item</span></a></li> </ul> </div> </div> </div> </div> </div> </div> </nav> </div> </div> </div> <div class="vector-column-end"> <div class="vector-sticky-pinned-container"> <nav class="vector-page-tools-landmark" aria-label="Page tools"> <div id="vector-page-tools-pinned-container" class="vector-pinned-container"> </div> </nav> <nav class="vector-appearance-landmark" aria-label="Appearance"> <div id="vector-appearance-pinned-container" class="vector-pinned-container"> <div id="vector-appearance" class="vector-appearance vector-pinnable-element"> <div class="vector-pinnable-header vector-appearance-pinnable-header vector-pinnable-header-pinned" data-feature-name="appearance-pinned" data-pinnable-element-id="vector-appearance" data-pinned-container-id="vector-appearance-pinned-container" data-unpinned-container-id="vector-appearance-unpinned-container" > <div class="vector-pinnable-header-label">Appearance</div> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-appearance.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-appearance.unpin">hide</button> </div> </div> </div> </nav> </div> </div> <div id="bodyContent" class="vector-body" aria-labelledby="firstHeading" data-mw-ve-target-container> <div class="vector-body-before-content"> <div class="mw-indicators"> </div> <div id="siteSub" class="noprint">From Wikipedia, the free encyclopedia</div> </div> <div id="contentSub"><div id="mw-content-subtitle"></div></div> <div id="mw-content-text" class="mw-body-content"><div class="mw-content-ltr mw-parser-output" lang="en" dir="ltr"><div class="shortdescription nomobile noexcerpt noprint searchaux" style="display:none">Chemical compound</div> <p class="mw-empty-elt"> </p> <style data-mw-deduplicate="TemplateStyles:r1257001546">.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}@media screen{html.skin-theme-clientpref-night .mw-parser-output .infobox-full-data:not(.notheme)>div:not(.notheme)[style]{background:#1f1f23!important;color:#f8f9fa}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .infobox-full-data:not(.notheme) div:not(.notheme){background:#1f1f23!important;color:#f8f9fa}}@media(min-width:640px){body.skin--responsive .mw-parser-output .infobox-table{display:table!important}body.skin--responsive .mw-parser-output .infobox-table>caption{display:table-caption!important}body.skin--responsive .mw-parser-output .infobox-table>tbody{display:table-row-group}body.skin--responsive .mw-parser-output .infobox-table tr{display:table-row!important}body.skin--responsive .mw-parser-output .infobox-table th,body.skin--responsive .mw-parser-output .infobox-table td{padding-left:inherit;padding-right:inherit}}</style><table class="infobox" style="border-spacing:2px;"><caption class="infobox-title"><span title="International nonproprietary name (INN): Inavolisib">Inavolisib</span></caption><tbody><tr><td colspan="2" class="infobox-image notheme" style="background-color: #f8f9fa;"><span class="mw-default-size" typeof="mw:File/Frameless"><a href="/wiki/File:Inavolisib.svg" class="mw-file-description"><img src="//upload.wikimedia.org/wikipedia/commons/thumb/2/28/Inavolisib.svg/220px-Inavolisib.svg.png" decoding="async" width="220" height="105" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/2/28/Inavolisib.svg/330px-Inavolisib.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/2/28/Inavolisib.svg/440px-Inavolisib.svg.png 2x" data-file-width="840" data-file-height="400" /></a></span></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd">Clinical data</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Drug_nomenclature#Trade_names" title="Drug nomenclature">Trade names</a></th><td class="infobox-data">Itovebi</td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;">Other names</th><td class="infobox-data">GDC-0077, RG6114, Ro7113755</td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/American_Society_of_Health-System_Pharmacists" title="American Society of Health-System Pharmacists">AHFS</a>/<a href="/wiki/Drugs.com" title="Drugs.com">Drugs.com</a></th><td class="infobox-data"><span title="www.drugs.com"><a rel="nofollow" class="external text" href="https://www.drugs.com/Itovebi.html">Itovebi</a></span></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">License data</a></th><td class="infobox-data"><style data-mw-deduplicate="TemplateStyles:r1126788409">.mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0}</style><div class="plainlist"> <ul><li><small><abbr class="country-name" title="United States">US</abbr></small> <a href="/wiki/DailyMed" title="DailyMed">DailyMed</a>: <span title="dailymed.nlm.nih.gov"><a rel="nofollow" class="external text" href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Inavolisib">Inavolisib</a></span></li></ul></div> </td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Route_of_administration" title="Route of administration">Routes of<br />administration</a></th><td class="infobox-data"><a href="/wiki/By_mouth" class="mw-redirect" title="By mouth">By mouth</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Drug_class" title="Drug class">Drug class</a></th><td class="infobox-data"><a href="/wiki/PI3K_inhibitor" class="mw-redirect" title="PI3K inhibitor">PI3K inhibitor</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li>None</li></ul></div></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd">Legal status</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Legal status</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"> <ul><li><small><abbr class="country-name" title="United States">US</abbr>:</small> <a href="/wiki/Prescription_drug" title="Prescription drug">℞-only</a><sup id="cite_ref-Itovebi_FDA_label_1-0" class="reference"><a href="#cite_note-Itovebi_FDA_label-1"><span class="cite-bracket">[</span>1<span class="cite-bracket">]</span></a></sup></li></ul></div> </td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd">Identifiers</th></tr><tr><td colspan="2" class="infobox-full-data"><div class="collapsible-list mw-collapsible mw-collapsed" style="text-align: left;"> <div style="line-height: 1.6em; font-weight: bold;"><div><a href="/wiki/IUPAC_nomenclature_of_chemistry" title="IUPAC nomenclature of chemistry">IUPAC name</a></div></div> <ul class="mw-collapsible-content" style="margin-top: 0; margin-bottom: 0; line-height: inherit; list-style: none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em;"><li style="line-height: inherit; margin: 0"><div style="font-size: 97%;">(2<i>S</i>)-2-[[2-[(4<i>S</i>)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide</div></li></ul> </div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/CAS_Registry_Number" title="CAS Registry Number">CAS Number</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="commonchemistry.cas.org"><a rel="nofollow" class="external text" href="https://commonchemistry.cas.org/detail?cas_rn=2060571-02-8">2060571-02-8</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/PubChem#CID" title="PubChem">PubChem</a> <span style="font-weight:normal"><abbr title="Compound ID">CID</abbr></span></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="pubchem.ncbi.nlm.nih.gov"><a rel="nofollow" class="external text" href="https://pubchem.ncbi.nlm.nih.gov/compound/124173720">124173720</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Guide_to_Pharmacology" title="Guide to Pharmacology">IUPHAR/BPS</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="www.guidetopharmacology.org"><a rel="nofollow" class="external text" href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9636">9636</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/DrugBank" title="DrugBank">DrugBank</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="www.drugbank.ca"><a rel="nofollow" class="external text" href="https://www.drugbank.ca/drugs/DB15275">DB15275</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/ChemSpider" title="ChemSpider">ChemSpider</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="www.chemspider.com"><a rel="nofollow" class="external text" href="https://www.chemspider.com/Chemical-Structure.59718498.html">59718498</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Unique_Ingredient_Identifier" title="Unique Ingredient Identifier">UNII</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="precision.fda.gov"><a rel="nofollow" class="external text" href="https://precision.fda.gov/uniisearch/srs/unii/L4C1UY2NYH">L4C1UY2NYH</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/KEGG" title="KEGG">KEGG</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="www.kegg.jp"><a rel="nofollow" class="external text" href="https://www.kegg.jp/entry/D11942">D11942</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/ChEMBL" title="ChEMBL">ChEMBL</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="www.ebi.ac.uk"><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/chembl/explore/compound/ChEMBL4650215">ChEMBL4650215</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Protein_Data_Bank" title="Protein Data Bank">PDB ligand</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li>X3N (<span title="www.ebi.ac.uk"><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=X3N">PDBe</a></span>, <span title="www.rcsb.org"><a rel="nofollow" class="external text" href="https://www.rcsb.org/ligand/X3N">RCSB PDB</a></span>)</li></ul></div></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Chemical_formula" title="Chemical formula">Formula</a></th><td class="infobox-data"><span title="Carbon">C</span><sub>18</sub><span title="Hydrogen">H</span><sub>19</sub><span title="Fluorine">F</span><sub>2</sub><span title="Nitrogen">N</span><sub>5</sub><span title="Oxygen">O</span><sub>4</sub></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Molar_mass" title="Molar mass">Molar mass</a></th><td class="infobox-data"><span class="nowrap"><span data-sort-value="7002407378000000000♠"></span>407.378</span> g·mol<sup>−1</sup></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;">3D model (<a href="/wiki/JSmol" class="mw-redirect" title="JSmol">JSmol</a>)</th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="chemapps.stolaf.edu (3D interactive model)"><a rel="nofollow" class="external text" href="https://chemapps.stolaf.edu/jmol/jmol.php?model=C%5BC%40%40H%5D%28C%28%3DO%29N%29NC1%3DCC2%3DC%28C%3DC1%29C3%3DNC%28%3DCN3CCO2%29N4%5BC%40%40H%5D%28COC4%3DO%29C%28F%29F">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" class="infobox-full-data"><div class="collapsible-list mw-collapsible mw-collapsed" style="text-align: left;"> <div style="line-height: 1.6em; font-weight: bold;"><div><a href="/wiki/Simplified_molecular-input_line-entry_system" class="mw-redirect" title="Simplified molecular-input line-entry system">SMILES</a></div></div> <ul class="mw-collapsible-content" style="margin-top: 0; margin-bottom: 0; line-height: inherit; list-style: none; margin-left: 0; word-break:break-all;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:97%; line-height:120%;">C[C@@H](C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4[C@@H](COC4=O)C(F)F</div></li></ul> </div></td></tr><tr><td colspan="2" class="infobox-full-data"><div class="collapsible-list mw-collapsible mw-collapsed" style="text-align: left;"> <div style="line-height: 1.6em; font-weight: bold;"><div><a href="/wiki/International_Chemical_Identifier" title="International Chemical Identifier">InChI</a></div></div> <ul class="mw-collapsible-content" style="margin-top: 0; margin-bottom: 0; line-height: inherit; list-style: none; margin-left: 0; word-break:break-all;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:97%; line-height:120%;">InChI=1S/C18H19F2N5O4/c1-9(16(21)26)22-10-2-3-11-13(6-10)28-5-4-24-7-14(23-17(11)24)25-12(15(19)20)8-29-18(25)27/h2-3,6-7,9,12,15,22H,4-5,8H2,1H3,(H2,21,26)/t9-,12-/m0/s1</div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:97%; line-height:120%;">Key:SGEUNORSOZVTOL-CABZTGNLSA-N</div></li></ul> </div></td></tr></tbody></table> <p><b>Inavolisib</b>, sold under the brand name <b>Itovebi</b>, is an <a href="/wiki/Anti-cancer_medication" class="mw-redirect" title="Anti-cancer medication">anti-cancer medication</a> used for the treatment of breast cancer.<sup id="cite_ref-Itovebi_FDA_label_1-1" class="reference"><a href="#cite_note-Itovebi_FDA_label-1"><span class="cite-bracket">[</span>1<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-FDA_20241010_2-0" class="reference"><a href="#cite_note-FDA_20241010-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> It is an <a href="/wiki/Phosphoinositide_3-kinase_inhibitor" title="Phosphoinositide 3-kinase inhibitor">inhibitor</a> and degrader of mutant <a href="/wiki/Phosphoinositide_3-kinase" title="Phosphoinositide 3-kinase">phosphatidylinositol 3-kinase (PI3K) alpha</a>.<sup id="cite_ref-Hanan_2022_3-0" class="reference"><a href="#cite_note-Hanan_2022-3"><span class="cite-bracket">[</span>3<span class="cite-bracket">]</span></a></sup> The PI3K-mediated signalling pathway has shown to play an important role in the development of tumours as dysregulation is commonly associated with tumour growth and resistance to antineoplastic agents and radiotherapy.<sup id="cite_ref-CID_124173720_4-0" class="reference"><a href="#cite_note-CID_124173720-4"><span class="cite-bracket">[</span>4<span class="cite-bracket">]</span></a></sup> </p><p>The most common adverse reactions include decreased neutrophils, decreased hemoglobin, increased fasting glucose, decreased platelets, decreased lymphocytes, stomatitis, diarrhea, decreased calcium, fatigue, decreased potassium, increased creatinine, increased ALT, nausea, decreased sodium, decreased magnesium, rash, decreased appetite, COVID-19 infection, and headache.<sup id="cite_ref-FDA_20241010_2-1" class="reference"><a href="#cite_note-FDA_20241010-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> </p><p>Inavolisib was approved by the US <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA) for treatment of <a href="/wiki/PIK3CA" class="mw-redirect" title="PIK3CA">PIK3CA</a>-mutant breast cancer in October 2024.<sup id="cite_ref-FDA_20241010_2-2" class="reference"><a href="#cite_note-FDA_20241010-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-:0_5-0" class="reference"><a href="#cite_note-:0-5"><span class="cite-bracket">[</span>5<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-6" class="reference"><a href="#cite_note-6"><span class="cite-bracket">[</span>6<span class="cite-bracket">]</span></a></sup> </p> <meta property="mw:PageProp/toc" /> <div class="mw-heading mw-heading2"><h2 id="Medical_uses">Medical uses</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=1" title="Edit section: Medical uses"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Inavolisib is <a href="/wiki/Indicated" class="mw-redirect" title="Indicated">indicated</a> in combination with <a href="/wiki/Palbociclib" title="Palbociclib">palbociclib</a> and <a href="/wiki/Fulvestrant" title="Fulvestrant">fulvestrant</a> for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.<sup id="cite_ref-FDA_20241010_2-3" class="reference"><a href="#cite_note-FDA_20241010-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Side_effects">Side effects</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=2" title="Edit section: Side effects"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>The most common adverse reactions include decreased neutrophils, decreased hemoglobin, increased fasting glucose, decreased platelets, decreased lymphocytes, stomatitis, diarrhea, decreased calcium, fatigue, decreased potassium, increased creatinine, increased ALT, nausea, decreased sodium, decreased magnesium, rash, decreased appetite, COVID-19 infection, and headache.<sup id="cite_ref-FDA_20241010_2-4" class="reference"><a href="#cite_note-FDA_20241010-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="History">History</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=3" title="Edit section: History"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Efficacy was evaluated in INAVO120 (NCT04191499), a randomized, double-blind, placebo-controlled, multicenter trial in 325 participants with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer whose disease progressed during or within twelve months of completing adjuvant endocrine therapy and who had not received prior systemic therapy for locally advanced or metastatic disease.<sup id="cite_ref-FDA_20241010_2-5" class="reference"><a href="#cite_note-FDA_20241010-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> Primary endocrine resistance was defined as relapse while on the first two years of adjuvant endocrine therapy (ET) and secondary endocrine resistance was defined as relapse while on adjuvant ET after at least two years or relapse within twelve months of completing adjuvant ET.<sup id="cite_ref-FDA_20241010_2-6" class="reference"><a href="#cite_note-FDA_20241010-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Structure,_reactivity,_and_synthesis"><span id="Structure.2C_reactivity.2C_and_synthesis"></span>Structure, reactivity, and synthesis</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=4" title="Edit section: Structure, reactivity, and synthesis"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Inavolisib is a synthetic, organic, small compound (the full structure can be seen <a rel="nofollow" class="external text" href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=9636">here</a>).<sup id="cite_ref-IUPHAR/BPS_Inavolisib_7-0" class="reference"><a href="#cite_note-IUPHAR/BPS_Inavolisib-7"><span class="cite-bracket">[</span>7<span class="cite-bracket">]</span></a></sup> When binding to phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (p110α), inavolisib’s carbonyl group can accept a <a href="/wiki/Hydrogen_bond" title="Hydrogen bond">hydrogen bond</a> from the Tyr836 (conserved) in p110α. The difluoromethyl group can interact with the hydroxyl group presented on Ser774 (conserved) in p110α, which is 3.2<a href="/wiki/Angstrom" title="Angstrom">Å</a> nearer than of which on the equivalent residue Ser754 in p110δ. Additionally, the amide group can interact with Gln859 (non-conserved). This results in a very high selectivity regarding PI3Kα isoforms.<sup id="cite_ref-Hanan_2022_3-1" class="reference"><a href="#cite_note-Hanan_2022-3"><span class="cite-bracket">[</span>3<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-8" class="reference"><a href="#cite_note-8"><span class="cite-bracket">[</span>8<span class="cite-bracket">]</span></a></sup> </p><p>Compared to similar PI3K inhibiting compounds, inavolisib has a higher thermodynamic aqueous solubility that proved advantageous in the formulation process and aiding greater consistency in predictions of absorption.<sup id="cite_ref-Hanan_2022_3-2" class="reference"><a href="#cite_note-Hanan_2022-3"><span class="cite-bracket">[</span>3<span class="cite-bracket">]</span></a></sup> </p><p>Inavolisibcan be developed as a derivative of <a href="/wiki/Oxazole" title="Oxazole">1,3-oxazole</a><sup id="cite_ref-9" class="reference"><a href="#cite_note-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup> or by means of stereo-controlled N-arylation of alpha-amino acids.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10"><span class="cite-bracket">[</span>10<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Metabolism_and_biotransformation">Metabolism and biotransformation</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=5" title="Edit section: Metabolism and biotransformation"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Inavolisib is orally administered, though there is little knowledge about its metabolism.<sup id="cite_ref-DB15275_11-0" class="reference"><a href="#cite_note-DB15275-11"><span class="cite-bracket">[</span>11<span class="cite-bracket">]</span></a></sup><sup class="noprint Inline-Template" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Identifying_reliable_sources_(medicine)" title="Wikipedia:Identifying reliable sources (medicine)"><span title="Material near this tag may rely on an unreliable or less reliable medical source. (October 2024)">unreliable medical source?</span></a></i>]</sup> However, absorption, metabolism, and excretion data of <a href="/wiki/Taselisib" title="Taselisib">taselisib</a>, a molecule with a related chemical scaffold, suggest moderately slow absorption into the systemic circulation, metabolism to play a minor role in drug clearance, and biliary excretion to be the main route of excretion.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12"><span class="cite-bracket">[</span>12<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Molecular_mechanisms_of_action">Molecular mechanisms of action</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=6" title="Edit section: Molecular mechanisms of action"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Inavolisib is a selective PI3K-p110α (<a href="/wiki/P110%CE%B1" title="P110α">PIK3CA</a>) inhibitor, which may offer antineoplastic functionality.<sup id="cite_ref-IUPHAR/BPS_Inavolisib_7-1" class="reference"><a href="#cite_note-IUPHAR/BPS_Inavolisib-7"><span class="cite-bracket">[</span>7<span class="cite-bracket">]</span></a></sup> Therefore, it may serve as a new addition to combination therapy with conventional cancer treatment, such as chemotherapy. Combining inavolisib with <a href="/wiki/Palbociclib" title="Palbociclib">palbociclib</a> and <a href="/wiki/Fulvestrant" title="Fulvestrant">fulvestrant</a> might improve treatment of <a href="/wiki/Breast_cancer" title="Breast cancer">breast cancer</a>.<sup id="cite_ref-13" class="reference"><a href="#cite_note-13"><span class="cite-bracket">[</span>13<span class="cite-bracket">]</span></a></sup> </p><p>Next to its inhibitory enzymatic ability, it is suggested that inavolisib binds to - and activates degradation of - mutated forms of p110α. Members of the PI3K family regulate cellular processes such as cell growth and proliferation, survival, remodelling, and intracellular transport of organelles.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14"><span class="cite-bracket">[</span>14<span class="cite-bracket">]</span></a></sup> PI3K also plays an essential role for the immune system. </p><p>The class I isoform PI3K alpha (PI3Kα) is often times expressed in solid tumours through gene amplification or activated mutations.<sup id="cite_ref-Hanan_2022_3-3" class="reference"><a href="#cite_note-Hanan_2022-3"><span class="cite-bracket">[</span>3<span class="cite-bracket">]</span></a></sup> Mutations in PI3Kα can often be found in cancer cells, especially HR+ breast cancer, which causes a disruption of the PI3K pathway. This leads to increased tumour growth and metastasis. One of the most common mutations can be found in <i>PIK3CA</i>, which plays a significant role in tumour cell proliferation. </p><p>In preclinical studies, inavolisib has shown to specifically initiate the degradation of this p110α oncogene with the help of proteasomes.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15"><span class="cite-bracket">[</span>15<span class="cite-bracket">]</span></a></sup> After binding to the mutant PI3Kα, inavolisib blocks phosphorylation of PIP<sub>2</sub> to PIP<sub>3</sub>, thereby stopping downstream signalling.<sup id="cite_ref-Genentech_Inavolisib_16-0" class="reference"><a href="#cite_note-Genentech_Inavolisib-16"><span class="cite-bracket">[</span>16<span class="cite-bracket">]</span></a></sup> </p><p>Consequently, biomarkers in the PI3K pathway are reduced, cell proliferation inhibited, and the rate of <i>PIK3CA</i>-mutant breast cancer apoptosis increased (in comparison to the wild type). The exact mechanism of action of inhibitors like inavolisib on mutated PI3Kα and the inhibitors' influence on mutant structures are still unknown.<sup id="cite_ref-17" class="reference"><a href="#cite_note-17"><span class="cite-bracket">[</span>17<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Toxicity">Toxicity</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=7" title="Edit section: Toxicity"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Inavolisib is able to induce a cytotoxic response but this is directed towards tumour cells that contain the PI3K mutation, thereby inhibiting further tumour growth and leading to cell loss.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18"><span class="cite-bracket">[</span>18<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Society_and_culture">Society and culture</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=8" title="Edit section: Society and culture"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <div class="mw-heading mw-heading3"><h3 id="Legal_status">Legal status</h3><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=9" title="Edit section: Legal status"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>In October 2024, the US <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> FDA approved inavolisib for the treatment of <a href="/wiki/PIK3CA" class="mw-redirect" title="PIK3CA">PIK3CA</a>-mutant breast cancer based on the results from the INAVO120 trial.<sup id="cite_ref-FDA_20241010_2-7" class="reference"><a href="#cite_note-FDA_20241010-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-Novel_Drug_Approvals_for_2024_19-0" class="reference"><a href="#cite_note-Novel_Drug_Approvals_for_2024-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-20" class="reference"><a href="#cite_note-20"><span class="cite-bracket">[</span>20<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-21" class="reference"><a href="#cite_note-21"><span class="cite-bracket">[</span>21<span class="cite-bracket">]</span></a></sup> The drug application was granted <a href="/wiki/Priority_review" title="Priority review">priority review</a> and <a href="/wiki/Breakthrough_therapy" title="Breakthrough therapy">breakthrough therapy</a> designations by the FDA.<sup id="cite_ref-FDA_20241010_2-8" class="reference"><a href="#cite_note-FDA_20241010-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-:0_5-1" class="reference"><a href="#cite_note-:0-5"><span class="cite-bracket">[</span>5<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-22" class="reference"><a href="#cite_note-22"><span class="cite-bracket">[</span>22<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading3"><h3 id="Names">Names</h3><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=10" title="Edit section: Names"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Inavolisib is the <a href="/wiki/International_nonproprietary_name" title="International nonproprietary name">international nonproprietary name</a>.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23"><span class="cite-bracket">[</span>23<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-24" class="reference"><a href="#cite_note-24"><span class="cite-bracket">[</span>24<span class="cite-bracket">]</span></a></sup> </p><p>Inavolisib is sold under the brand name Itovebi.<sup id="cite_ref-FDA_20241010_2-9" class="reference"><a href="#cite_note-FDA_20241010-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Research">Research</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=11" title="Edit section: Research"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Due to inavolisib’s ability to inhibit the PI3K pathway through <a href="/wiki/HER2" title="HER2">HER2</a>-dependent degradation, it is undergoing clinical trials to potentially make use of it as an antineoplastic (anti-cancer) drug to treat <a href="/wiki/Breast_cancer" title="Breast cancer">breast cancer</a>.<sup id="cite_ref-Hanan_2022_3-4" class="reference"><a href="#cite_note-Hanan_2022-3"><span class="cite-bracket">[</span>3<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-Vanhaesebroeck_2022_25-0" class="reference"><a href="#cite_note-Vanhaesebroeck_2022-25"><span class="cite-bracket">[</span>25<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-Genentech_Inavolisib_16-1" class="reference"><a href="#cite_note-Genentech_Inavolisib-16"><span class="cite-bracket">[</span>16<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="References">References</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=12" title="Edit section: References"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <style data-mw-deduplicate="TemplateStyles:r1239543626">.mw-parser-output .reflist{margin-bottom:0.5em;list-style-type:decimal}@media screen{.mw-parser-output .reflist{font-size:90%}}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}</style><div class="reflist"> <div class="mw-references-wrap mw-references-columns"><ol class="references"> <li id="cite_note-Itovebi_FDA_label-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-Itovebi_FDA_label_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Itovebi_FDA_label_1-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><style data-mw-deduplicate="TemplateStyles:r1238218222">.mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free.id-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited.id-lock-limited a,.mw-parser-output .id-lock-registration.id-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription.id-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-free a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-limited a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-registration a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-subscription a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .cs1-ws-icon a{background-size:contain;padding:0 1em 0 0}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:var(--color-error,#d33)}.mw-parser-output .cs1-visible-error{color:var(--color-error,#d33)}.mw-parser-output .cs1-maint{display:none;color:#085;margin-left:0.3em}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}@media screen{.mw-parser-output .cs1-format{font-size:95%}html.skin-theme-clientpref-night .mw-parser-output .cs1-maint{color:#18911f}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .cs1-maint{color:#18911f}}</style><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5de59f5b-e5db-410f-b692-658686ef4107">"Itovebi- inavolisib tablet, film coated"</a>. <i>DailyMed</i>. 11 October 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">11 November</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=DailyMed&rft.atitle=Itovebi-+inavolisib+tablet%2C+film+coated&rft.date=2024-10-11&rft_id=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D5de59f5b-e5db-410f-b692-658686ef4107&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-FDA_20241010-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_20241010_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_20241010_2-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_20241010_2-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_20241010_2-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_20241010_2-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDA_20241010_2-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-FDA_20241010_2-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-FDA_20241010_2-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-FDA_20241010_2-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-FDA_20241010_2-9"><sup><i><b>j</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive">"FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 10 October 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">11 October</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+inavolisib+with+palbociclib+and+fulvestrant+for+endocrine-resistant%2C+PIK3CA-mutated%2C+HR-positive%2C+HER2-negative%2C+advanced+breast+cancer&rft.date=2024-10-10&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-Hanan_2022-3"><span class="mw-cite-backlink">^ <a href="#cite_ref-Hanan_2022_3-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Hanan_2022_3-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Hanan_2022_3-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Hanan_2022_3-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Hanan_2022_3-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFHananBraunHealdMacLeod2022" class="citation journal cs1">Hanan EJ, Braun MG, Heald RA, MacLeod C, Chan C, Clausen S, et al. (December 2022). "Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα". <i>Journal of Medicinal Chemistry</i>. <b>65</b> (24). American Chemical Society (ACS): 16589–16621. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1021%2Facs.jmedchem.2c01422">10.1021/acs.jmedchem.2c01422</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/36455032">36455032</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:254149451">254149451</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Journal+of+Medicinal+Chemistry&rft.atitle=Discovery+of+GDC-0077+%28Inavolisib%29%2C+a+Highly+Selective+Inhibitor+and+Degrader+of+Mutant+PI3K%CE%B1&rft.volume=65&rft.issue=24&rft.pages=16589-16621&rft.date=2022-12&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A254149451%23id-name%3DS2CID&rft_id=info%3Apmid%2F36455032&rft_id=info%3Adoi%2F10.1021%2Facs.jmedchem.2c01422&rft.aulast=Hanan&rft.aufirst=EJ&rft.au=Braun%2C+MG&rft.au=Heald%2C+RA&rft.au=MacLeod%2C+C&rft.au=Chan%2C+C&rft.au=Clausen%2C+S&rft.au=Edgar%2C+KA&rft.au=Eigenbrot%2C+C&rft.au=Elliott%2C+R&rft.au=Endres%2C+N&rft.au=Friedman%2C+LS&rft.au=Gogol%2C+E&rft.au=Gu%2C+XH&rft.au=Thibodeau%2C+RH&rft.au=Jackson%2C+PS&rft.au=Kiefer%2C+JR&rft.au=Knight%2C+JD&rft.au=Nannini%2C+M&rft.au=Narukulla%2C+R&rft.au=Pace%2C+A&rft.au=Pang%2C+J&rft.au=Purkey%2C+HE&rft.au=Salphati%2C+L&rft.au=Sampath%2C+D&rft.au=Schmidt%2C+S&rft.au=Sideris%2C+S&rft.au=Song%2C+K&rft.au=Sujatha-Bhaskar%2C+S&rft.au=Ultsch%2C+M&rft.au=Wallweber%2C+H&rft.au=Xin%2C+J&rft.au=Yeap%2C+S&rft.au=Young%2C+A&rft.au=Zhong%2C+Y&rft.au=Staben%2C+ST&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-CID_124173720-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-CID_124173720_4-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://pubchem.ncbi.nlm.nih.gov/compound/Inavolisib#section=3D-Conformer">"CID 124173720, Inavolisib"</a>. <i>PubChem</i>. National Center for Biotechnology Information, U.S. National Library of Medicine<span class="reference-accessdate">. Retrieved <span class="nowrap">21 September</span> 2023</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=PubChem&rft.atitle=CID+124173720%2C+Inavolisib&rft_id=https%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fcompound%2FInavolisib%23section%3D3D-Conformer&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-:0-5"><span class="mw-cite-backlink">^ <a href="#cite_ref-:0_5-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:0_5-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.targetedonc.com/view/fda-approves-inavolisib-plus-standard-therapy-in-pik3ca-mutant-breast-cancer">"FDA Approves Inavolisib Plus Standard Therapy in PIK3CA-Mutant Breast Cancer"</a>. <i>Targeted Oncology</i>. 10 October 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">11 October</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Targeted+Oncology&rft.atitle=FDA+Approves+Inavolisib+Plus+Standard+Therapy+in+PIK3CA-Mutant+Breast+Cancer&rft.date=2024-10-10&rft_id=https%3A%2F%2Fwww.targetedonc.com%2Fview%2Ffda-approves-inavolisib-plus-standard-therapy-in-pik3ca-mutant-breast-cancer&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">"Novel Drug Approvals for 2024"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 8 November 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">8 November</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=Novel+Drug+Approvals+for+2024&rft.date=2024-11-08&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fnovel-drug-approvals-fda%2Fnovel-drug-approvals-2024&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-IUPHAR/BPS_Inavolisib-7"><span class="mw-cite-backlink">^ <a href="#cite_ref-IUPHAR/BPS_Inavolisib_7-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-IUPHAR/BPS_Inavolisib_7-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=9636">"inavolisib — Ligand page"</a>. <i>IUPHAR/BPS Guide to Pharmacology</i><span class="reference-accessdate">. Retrieved <span class="nowrap">21 September</span> 2023</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=IUPHAR%2FBPS+Guide+to+Pharmacology&rft.atitle=inavolisib+%E2%80%94+Ligand+page&rft_id=https%3A%2F%2Fwww.guidetopharmacology.org%2FGRAC%2FLigandDisplayForward%3Ftab%3Dclinical%26ligandId%3D9636&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFVanhaesebroeckPerryBrownAndré2021" class="citation journal cs1">Vanhaesebroeck B, Perry MW, Brown JR, André F, Okkenhaug K (October 2021). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297732">"PI3K inhibitors are finally coming of age"</a>. <i>Nature Reviews. Drug Discovery</i>. <b>20</b> (10). Springer Science and Business Media LLC: 741–769. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Fs41573-021-00209-1">10.1038/s41573-021-00209-1</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297732">9297732</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/34127844">34127844</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Nature+Reviews.+Drug+Discovery&rft.atitle=PI3K+inhibitors+are+finally+coming+of+age&rft.volume=20&rft.issue=10&rft.pages=741-769&rft.date=2021-10&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9297732%23id-name%3DPMC&rft_id=info%3Apmid%2F34127844&rft_id=info%3Adoi%2F10.1038%2Fs41573-021-00209-1&rft.aulast=Vanhaesebroeck&rft.aufirst=B&rft.au=Perry%2C+MW&rft.au=Brown%2C+JR&rft.au=Andr%C3%A9%2C+F&rft.au=Okkenhaug%2C+K&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9297732&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-9">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFChenLvLiuYu2021" class="citation journal cs1">Chen J, Lv S, Liu J, Yu Y, Wang H, Zhang H (December 2021). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706051">"An Overview of Bioactive 1,3-Oxazole-Containing Alkaloids from Marine Organisms"</a>. <i>Pharmaceuticals</i>. <b>14</b> (12). MDPI AG: 1274. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.3390%2Fph14121274">10.3390/ph14121274</a></span>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706051">8706051</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/34959674">34959674</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Pharmaceuticals&rft.atitle=An+Overview+of+Bioactive+1%2C3-Oxazole-Containing+Alkaloids+from+Marine+Organisms&rft.volume=14&rft.issue=12&rft.pages=1274&rft.date=2021-12&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8706051%23id-name%3DPMC&rft_id=info%3Apmid%2F34959674&rft_id=info%3Adoi%2F10.3390%2Fph14121274&rft.aulast=Chen&rft.aufirst=J&rft.au=Lv%2C+S&rft.au=Liu%2C+J&rft.au=Yu%2C+Y&rft.au=Wang%2C+H&rft.au=Zhang%2C+H&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC8706051&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-10">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFHanKellyCravillionSavage2019" class="citation journal cs1">Han C, Kelly SM, Cravillion T, Savage SJ, Nguyen T, Gosselin F (2019). "Synthesis of PI3K inhibitor GDC-0077 via a stereocontrolled N-arylation of α-amino acids". <i>Tetrahedron</i>. <b>75</b> (32). Elsevier BV: 4351–4357. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.tet.2019.04.057">10.1016/j.tet.2019.04.057</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a> <a rel="nofollow" class="external text" href="https://search.worldcat.org/issn/0040-4020">0040-4020</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:150262658">150262658</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Tetrahedron&rft.atitle=Synthesis+of+PI3K+inhibitor+GDC-0077+via+a+stereocontrolled+N-arylation+of+%CE%B1-amino+acids&rft.volume=75&rft.issue=32&rft.pages=4351-4357&rft.date=2019&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A150262658%23id-name%3DS2CID&rft.issn=0040-4020&rft_id=info%3Adoi%2F10.1016%2Fj.tet.2019.04.057&rft.aulast=Han&rft.aufirst=C&rft.au=Kelly%2C+SM&rft.au=Cravillion%2C+T&rft.au=Savage%2C+SJ&rft.au=Nguyen%2C+T&rft.au=Gosselin%2C+F&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-DB15275-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-DB15275_11-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://go.drugbank.com/drugs/DB15275">"Inavolisib: Uses, Interactions, Mechanism of Action"</a>. <i>DrugBank</i>. 20 May 2019. DB15275<span class="reference-accessdate">. Retrieved <span class="nowrap">21 September</span> 2023</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=DrugBank&rft.atitle=Inavolisib%3A+Uses%2C+Interactions%2C+Mechanism+of+Action&rft.date=2019-05-20&rft_id=https%3A%2F%2Fgo.drugbank.com%2Fdrugs%2FDB15275&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFMaChoSahasranamanZhao2023" class="citation journal cs1">Ma S, Cho S, Sahasranaman S, Zhao W, Pang J, Ding X, et al. (April 2023). "Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent <i>β</i>-Sparing PI3K Inhibitor in Rats, Dogs, and Humans". <i>Drug Metabolism and Disposition</i>. <b>51</b> (4): 436–450. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1124%2Fdmd.122.001096">10.1124/dmd.122.001096</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/36623882">36623882</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Drug+Metabolism+and+Disposition&rft.atitle=Absorption%2C+Metabolism%2C+and+Excretion+of+Taselisib+%28GDC-0032%29%2C+a+Potent+%3Ci%3E%CE%B2%3C%2Fi%3E-Sparing+PI3K+Inhibitor+in+Rats%2C+Dogs%2C+and+Humans&rft.volume=51&rft.issue=4&rft.pages=436-450&rft.date=2023-04&rft_id=info%3Adoi%2F10.1124%2Fdmd.122.001096&rft_id=info%3Apmid%2F36623882&rft.aulast=Ma&rft.aufirst=S&rft.au=Cho%2C+S&rft.au=Sahasranaman%2C+S&rft.au=Zhao%2C+W&rft.au=Pang%2C+J&rft.au=Ding%2C+X&rft.au=Dean%2C+B&rft.au=Wang%2C+B&rft.au=Hsu%2C+JY&rft.au=Ware%2C+J&rft.au=Salphati%2C+L&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-a-new-drug-called-inavolisib-for-breast-cancer-that-has-spread-wo41554">"A trial looking at a new drug called inavolisib for breast cancer that has spread (WO41554)"</a>. <i>Cancer Research UK</i>. 22 June 2021<span class="reference-accessdate">. Retrieved <span class="nowrap">21 September</span> 2023</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Cancer+Research+UK&rft.atitle=A+trial+looking+at+a+new+drug+called+inavolisib+for+breast+cancer+that+has+spread+%28WO41554%29&rft.date=2021-06-22&rft_id=https%3A%2F%2Fwww.cancerresearchuk.org%2Fabout-cancer%2Ffind-a-clinical-trial%2Fa-trial-looking-at-a-new-drug-called-inavolisib-for-breast-cancer-that-has-spread-wo41554&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFKoyasu2003" class="citation journal cs1">Koyasu S (April 2003). "The role of PI3K in immune cells". <i>Nature Immunology</i>. <b>4</b> (4). Springer Science and Business Media LLC: 313–319. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Fni0403-313">10.1038/ni0403-313</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/12660731">12660731</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:9951653">9951653</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Nature+Immunology&rft.atitle=The+role+of+PI3K+in+immune+cells&rft.volume=4&rft.issue=4&rft.pages=313-319&rft.date=2003-04&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A9951653%23id-name%3DS2CID&rft_id=info%3Apmid%2F12660731&rft_id=info%3Adoi%2F10.1038%2Fni0403-313&rft.aulast=Koyasu&rft.aufirst=S&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFHongEdgarSongSteven2018" class="citation journal cs1">Hong R, Edgar K, Song K, Steven S, Young A, Hamilton P, et al. (15 February 2018). "Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in <i>PIK3CA</i> mutant breast cancer models as a single agent and in combination with standard of care therapies". <i>Cancer Research</i>. <b>78</b> (4_Supplement). American Association for Cancer Research (AACR): PD4–14–PD4–14. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1158%2F1538-7445.sabcs17-pd4-14">10.1158/1538-7445.sabcs17-pd4-14</a>. <a href="/wiki/ISSN_(identifier)" class="mw-redirect" title="ISSN (identifier)">ISSN</a> <a rel="nofollow" class="external text" href="https://search.worldcat.org/issn/0008-5472">0008-5472</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Cancer+Research&rft.atitle=Abstract+PD4-14%3A+GDC-0077+is+a+selective+PI3Kalpha+inhibitor+that+demonstrates+robust+efficacy+in+PIK3CA+mutant+breast+cancer+models+as+a+single+agent+and+in+combination+with+standard+of+care+therapies&rft.volume=78&rft.issue=4_Supplement&rft.pages=PD4-14-PD4-14&rft.date=2018-02-15&rft_id=info%3Adoi%2F10.1158%2F1538-7445.sabcs17-pd4-14&rft.issn=0008-5472&rft.aulast=Hong&rft.aufirst=R&rft.au=Edgar%2C+K&rft.au=Song%2C+K&rft.au=Steven%2C+S&rft.au=Young%2C+A&rft.au=Hamilton%2C+P&rft.au=Arrazate%2C+A&rft.au=De+La+Cruz%2C+C&rft.au=Chan%2C+C&rft.au=Pang%2C+J&rft.au=Salphati%2C+L&rft.au=Belvin%2C+M&rft.au=Nannini%2C+M&rft.au=Staben%2C+S&rft.au=Friedman%2C+L&rft.au=Sampath%2C+D&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-Genentech_Inavolisib-16"><span class="mw-cite-backlink">^ <a href="#cite_ref-Genentech_Inavolisib_16-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Genentech_Inavolisib_16-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.genentechoncology.com/pipeline-molecules/inavolisib.html">"Inavolisib (PI3K alpha inhibitor)"</a>. <i>Genentech</i><span class="reference-accessdate">. Retrieved <span class="nowrap">21 September</span> 2023</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Genentech&rft.atitle=Inavolisib+%28PI3K+alpha+inhibitor%29&rft_id=https%3A%2F%2Fwww.genentechoncology.com%2Fpipeline-molecules%2Finavolisib.html&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-17">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFMenteşKarakuzuluUçarYandım2022" class="citation journal cs1">Menteş M, Karakuzulu BB, Uçar GB, Yandım C (August 2022). "Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP". <i>Computational Biology and Chemistry</i>. <b>99</b>. Elsevier BV: 107726. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.compbiolchem.2022.107726">10.1016/j.compbiolchem.2022.107726</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/35842959">35842959</a>. <a href="/wiki/S2CID_(identifier)" class="mw-redirect" title="S2CID (identifier)">S2CID</a> <a rel="nofollow" class="external text" href="https://api.semanticscholar.org/CorpusID:250404770">250404770</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Computational+Biology+and+Chemistry&rft.atitle=Comparative+molecular+dynamics+analyses+on+PIK3CA+hotspot+mutations+with+PI3K%CE%B1+specific+inhibitors+and+ATP&rft.volume=99&rft.pages=107726&rft.date=2022-08&rft_id=https%3A%2F%2Fapi.semanticscholar.org%2FCorpusID%3A250404770%23id-name%3DS2CID&rft_id=info%3Apmid%2F35842959&rft_id=info%3Adoi%2F10.1016%2Fj.compbiolchem.2022.107726&rft.aulast=Mente%C5%9F&rft.aufirst=M&rft.au=Karakuzulu%2C+BB&rft.au=U%C3%A7ar%2C+GB&rft.au=Yand%C4%B1m%2C+C&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-18">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFSongEdgarHananHafner2022" class="citation journal cs1">Song KW, Edgar KA, Hanan EJ, Hafner M, Oeh J, Merchant M, et al. (January 2022). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762331">"RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy"</a>. <i>Cancer Discovery</i>. <b>12</b> (1). American Association for Cancer Research (AACR): 204–219. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1158%2F2159-8290.cd-21-0072">10.1158/2159-8290.cd-21-0072</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762331">9762331</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/34544753">34544753</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Cancer+Discovery&rft.atitle=RTK-Dependent+Inducible+Degradation+of+Mutant+PI3K%CE%B1+Drives+GDC-0077+%28Inavolisib%29+Efficacy&rft.volume=12&rft.issue=1&rft.pages=204-219&rft.date=2022-01&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9762331%23id-name%3DPMC&rft_id=info%3Apmid%2F34544753&rft_id=info%3Adoi%2F10.1158%2F2159-8290.cd-21-0072&rft.aulast=Song&rft.aufirst=KW&rft.au=Edgar%2C+KA&rft.au=Hanan%2C+EJ&rft.au=Hafner%2C+M&rft.au=Oeh%2C+J&rft.au=Merchant%2C+M&rft.au=Sampath%2C+D&rft.au=Nannini%2C+MA&rft.au=Hong%2C+R&rft.au=Phu%2C+L&rft.au=Forrest%2C+WF&rft.au=Stawiski%2C+E&rft.au=Schmidt%2C+S&rft.au=Endres%2C+N&rft.au=Guan%2C+J&rft.au=Wallin%2C+JJ&rft.au=Cheong%2C+J&rft.au=Plise%2C+EG&rft.au=Lewis+Phillips%2C+GD&rft.au=Salphati%2C+L&rft.au=Heffron%2C+TP&rft.au=Olivero%2C+AG&rft.au=Malek%2C+S&rft.au=Staben%2C+ST&rft.au=Kirkpatrick%2C+DS&rft.au=Dey%2C+A&rft.au=Friedman%2C+LS&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC9762331&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-Novel_Drug_Approvals_for_2024-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-Novel_Drug_Approvals_for_2024_19-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">"Novel Drug Approvals for 2024"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 1 October 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">29 November</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=Novel+Drug+Approvals+for+2024&rft.date=2024-10-01&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fnovel-drug-approvals-fda%2Fnovel-drug-approvals-2024&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://www.businesswire.com/news/home/20241008295168/en/FDA-Approves-Genentech%E2%80%99s-Itovebi-a-Targeted-Treatment-for-Advanced-Hormone-Receptor-Positive-HER2-Negative-Breast-Cancer-With-a-PIK3CA-Mutation">"FDA Approves Genentech's Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation"</a> (Press release). Genentech. 10 October 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">11 October</span> 2024</span> – via Business Wire.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+Approves+Genentech%27s+Itovebi%2C+a+Targeted+Treatment+for+Advanced+Hormone+Receptor-Positive%2C+HER2-Negative+Breast+Cancer+With+a+PIK3CA+Mutation&rft.pub=Genentech&rft.date=2024-10-10&rft_id=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20241008295168%2Fen%2FFDA-Approves-Genentech%25E2%2580%2599s-Itovebi-a-Targeted-Treatment-for-Advanced-Hormone-Receptor-Positive-HER2-Negative-Breast-Cancer-With-a-PIK3CA-Mutation&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://www.businesswire.com/news/home/20241011935278/en/U.S.-Food-and-Drug-Administration-Approves-FoundationOne%C2%AELiquid-CDx-as-a-Companion-Diagnostic-for-Itovebi%E2%84%A2-inavolisib-to-Identify-Patients-with-Hormone-Receptor-Positive-HER2-Negative-Breast-Cancer-with-a-PIK3CA-Mutation">"U.S. Food and Drug Administration Approves FoundationOne Liquid CDx as a Companion Diagnostic for Itovebi (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation"</a> (Press release). Foundation Medicine. 11 October 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">11 October</span> 2024</span> – via Business Wire.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=U.S.+Food+and+Drug+Administration+Approves+FoundationOne+Liquid+CDx+as+a+Companion+Diagnostic+for+Itovebi+%28inavolisib%29+to+Identify+Patients+with+Hormone+Receptor-Positive%2C+HER2-Negative+Breast+Cancer+with+a+PIK3CA+Mutation&rft.pub=Foundation+Medicine&rft.date=2024-10-11&rft_id=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20241011935278%2Fen%2FU.S.-Food-and-Drug-Administration-Approves-FoundationOne%25C2%25AELiquid-CDx-as-a-Companion-Diagnostic-for-Itovebi%25E2%2584%25A2-inavolisib-to-Identify-Patients-with-Hormone-Receptor-Positive-HER2-Negative-Breast-Cancer-with-a-PIK3CA-Mutation&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.onclive.com/view/fda-approves-inavolisib-plus-palbociclib-fulvestrant-for-endocrine-resistant-pik3ca-mutated-hr-her2-advanced-breast-cancer">"FDA Approves Inavolisib Plus Palbociclib/Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Advanced Breast Cancer"</a>. <i>OncLive</i>. 10 October 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">11 October</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=OncLive&rft.atitle=FDA+Approves+Inavolisib+Plus+Palbociclib%2FFulvestrant+for+Endocrine-Resistant%2C+PIK3CA-Mutated%2C+HR%2B%2C+HER2%E2%80%93+Advanced+Breast+Cancer&rft.date=2024-10-10&rft_id=https%3A%2F%2Fwww.onclive.com%2Fview%2Ffda-approves-inavolisib-plus-palbociclib-fulvestrant-for-endocrine-resistant-pik3ca-mutated-hr-her2-advanced-breast-cancer&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFWorld_Health_Organization2020" class="citation journal cs1"><a href="/wiki/World_Health_Organization" title="World Health Organization">World Health Organization</a> (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 84". <i>WHO Drug Information</i>. <b>34</b> (3). <a href="/wiki/Hdl_(identifier)" class="mw-redirect" title="Hdl (identifier)">hdl</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://hdl.handle.net/10665%2F340680">10665/340680</a></span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=WHO+Drug+Information&rft.atitle=International+nonproprietary+names+for+pharmaceutical+substances+%28INN%29%3A+recommended+INN%3A+list+84&rft.volume=34&rft.issue=3&rft.date=2020&rft_id=info%3Ahdl%2F10665%2F340680&rft.au=World+Health+Organization&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFWorld_Health_Organization2023" class="citation journal cs1"><a href="/wiki/World_Health_Organization" title="World Health Organization">World Health Organization</a> (2023). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 90". <i>WHO Drug Information</i>. <b>37</b> (3). <a href="/wiki/Hdl_(identifier)" class="mw-redirect" title="Hdl (identifier)">hdl</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://hdl.handle.net/10665%2F373341">10665/373341</a></span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=WHO+Drug+Information&rft.atitle=International+nonproprietary+names+for+pharmaceutical+substances+%28INN%29%3A+recommended+INN%3A+list+90&rft.volume=37&rft.issue=3&rft.date=2023&rft_id=info%3Ahdl%2F10665%2F373341&rft.au=World+Health+Organization&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> <li id="cite_note-Vanhaesebroeck_2022-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-Vanhaesebroeck_2022_25-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFVanhaesebroeckBurkeMadsen2022" class="citation journal cs1">Vanhaesebroeck B, Burke JE, Madsen RR (January 2022). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612218">"Precision Targeting of Mutant PI3Kα in Cancer by Selective Degradation"</a>. <i>Cancer Discovery</i>. <b>12</b> (1). American Association for Cancer Research (AACR): 20–22. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1158%2F2159-8290.cd-21-1411">10.1158/2159-8290.cd-21-1411</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612218">7612218</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/35022207">35022207</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Cancer+Discovery&rft.atitle=Precision+Targeting+of+Mutant+PI3K%CE%B1+in+Cancer+by+Selective+Degradation&rft.volume=12&rft.issue=1&rft.pages=20-22&rft.date=2022-01&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7612218%23id-name%3DPMC&rft_id=info%3Apmid%2F35022207&rft_id=info%3Adoi%2F10.1158%2F2159-8290.cd-21-1411&rft.aulast=Vanhaesebroeck&rft.aufirst=B&rft.au=Burke%2C+JE&rft.au=Madsen%2C+RR&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7612218&rfr_id=info%3Asid%2Fen.wikipedia.org%3AInavolisib" class="Z3988"></span></span> </li> </ol></div></div> <div class="mw-heading mw-heading2"><h2 id="External_links">External links</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Inavolisib&action=edit&section=13" title="Edit section: External links"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <ul><li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT04191499">NCT04191499</a></i> for "A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li></ul> <div class="navbox-styles"><style data-mw-deduplicate="TemplateStyles:r1129693374">.mw-parser-output .hlist dl,.mw-parser-output .hlist ol,.mw-parser-output .hlist ul{margin:0;padding:0}.mw-parser-output .hlist dd,.mw-parser-output .hlist dt,.mw-parser-output .hlist li{margin:0;display:inline}.mw-parser-output .hlist.inline,.mw-parser-output .hlist.inline dl,.mw-parser-output .hlist.inline ol,.mw-parser-output .hlist.inline ul,.mw-parser-output .hlist dl dl,.mw-parser-output .hlist dl ol,.mw-parser-output .hlist dl ul,.mw-parser-output .hlist ol dl,.mw-parser-output .hlist ol ol,.mw-parser-output .hlist ol ul,.mw-parser-output .hlist ul dl,.mw-parser-output .hlist ul ol,.mw-parser-output .hlist ul ul{display:inline}.mw-parser-output .hlist .mw-empty-li{display:none}.mw-parser-output .hlist dt::after{content:": "}.mw-parser-output .hlist dd::after,.mw-parser-output .hlist li::after{content:" · ";font-weight:bold}.mw-parser-output .hlist dd:last-child::after,.mw-parser-output .hlist dt:last-child::after,.mw-parser-output .hlist li:last-child::after{content:none}.mw-parser-output .hlist dd dd:first-child::before,.mw-parser-output .hlist dd dt:first-child::before,.mw-parser-output .hlist dd li:first-child::before,.mw-parser-output .hlist dt dd:first-child::before,.mw-parser-output .hlist dt dt:first-child::before,.mw-parser-output .hlist dt li:first-child::before,.mw-parser-output .hlist li dd:first-child::before,.mw-parser-output .hlist li dt:first-child::before,.mw-parser-output .hlist li li:first-child::before{content:" (";font-weight:normal}.mw-parser-output .hlist dd dd:last-child::after,.mw-parser-output .hlist dd dt:last-child::after,.mw-parser-output .hlist dd li:last-child::after,.mw-parser-output .hlist dt dd:last-child::after,.mw-parser-output .hlist dt dt:last-child::after,.mw-parser-output .hlist dt li:last-child::after,.mw-parser-output .hlist li dd:last-child::after,.mw-parser-output .hlist li dt:last-child::after,.mw-parser-output .hlist li li:last-child::after{content:")";font-weight:normal}.mw-parser-output .hlist ol{counter-reset:listitem}.mw-parser-output .hlist ol>li{counter-increment:listitem}.mw-parser-output .hlist ol>li::before{content:" "counter(listitem)"\a0 "}.mw-parser-output .hlist dd ol>li:first-child::before,.mw-parser-output .hlist dt ol>li:first-child::before,.mw-parser-output .hlist li ol>li:first-child::before{content:" ("counter(listitem)"\a0 "}</style><style data-mw-deduplicate="TemplateStyles:r1236075235">.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}body.skin--responsive .mw-parser-output .navbox-image img{max-width:none!important}@media print{body.ns-0 .mw-parser-output .navbox{display:none!important}}</style></div><div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"><style data-mw-deduplicate="TemplateStyles:r1239400231">.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}html.skin-theme-clientpref-night .mw-parser-output .navbar li a abbr{color:var(--color-base)!important}@media(prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .navbar li a abbr{color:var(--color-base)!important}}@media print{.mw-parser-output .navbar{display:none!important}}</style><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:Targeted_cancer_therapeutic_agents" title="Template:Targeted cancer therapeutic agents"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Targeted_cancer_therapeutic_agents" title="Template talk:Targeted cancer therapeutic agents"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a href="/wiki/Special:EditPage/Template:Targeted_cancer_therapeutic_agents" title="Special:EditPage/Template:Targeted cancer therapeutic agents"><abbr title="Edit this template">e</abbr></a></li></ul></div><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em"><a href="/wiki/Targeted_cancer_therapy" class="mw-redirect" title="Targeted cancer therapy">Targeted cancer therapy</a> / <a href="/wiki/Antineoplastic" class="mw-redirect" title="Antineoplastic">antineoplastic agents</a> (<a href="/wiki/ATC_code_L01" title="ATC code L01">L01</a>)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Cancer_immunotherapy" title="Cancer immunotherapy">CI</a> <a href="/wiki/Monoclonal_antibody_therapy" title="Monoclonal antibody therapy">monoclonal antibodies</a> ("-mab")</th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Receptor_tyrosine_kinase" title="Receptor tyrosine kinase">Receptor tyrosine kinase</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/ErbB" title="ErbB">ErbB</a>: <i><a href="/wiki/Epidermal_growth_factor_receptor" title="Epidermal growth factor receptor">HER1/EGFR</a></i> (<a href="/wiki/Cetuximab" title="Cetuximab">Cetuximab</a></li> <li><a href="/wiki/Panitumumab" title="Panitumumab">Panitumumab</a>)</li> <li><i><a href="/wiki/HER2/neu" class="mw-redirect" title="HER2/neu">HER2/neu</a></i> (<a href="/wiki/Pertuzumab" title="Pertuzumab">Pertuzumab</a></li> <li><a href="/wiki/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (<a href="/wiki/Trastuzumab/hyaluronidase" title="Trastuzumab/hyaluronidase">+hyaluronidase</a>)</li> <li><a href="/wiki/Trastuzumab_emtansine" title="Trastuzumab emtansine">Trastuzumab emtansine</a></li> <li><a href="/wiki/Trastuzumab_deruxtecan" title="Trastuzumab deruxtecan">Trastuzumab deruxtecan</a></li> <li><a href="/wiki/Zanidatamab" title="Zanidatamab">Zanidatamab</a> )</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><i><a href="/wiki/EpCAM" class="mw-redirect" title="EpCAM">EpCAM</a></i> (<a href="/wiki/Catumaxomab" title="Catumaxomab">Catumaxomab</a></li> <li><a href="/wiki/Edrecolomab" title="Edrecolomab">Edrecolomab</a>)</li> <li><i><a href="/wiki/Vascular_endothelial_growth_factor_A" title="Vascular endothelial growth factor A">VEGF-A</a></i> (<a href="/wiki/Bevacizumab" title="Bevacizumab">Bevacizumab</a>)</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Leukemia" title="Leukemia">Leukemia</a>/<a href="/wiki/Lymphoma" title="Lymphoma">lymphoma</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Lymphatic_system" title="Lymphatic system">lymphoid</a>: <i><a href="/wiki/CD3_(immunology)" title="CD3 (immunology)">CD3</a></i> (<a href="/wiki/Glofitamab" title="Glofitamab">Glofitamab</a>, <a href="/wiki/Elranatamab" title="Elranatamab">Elranatamab</a>, <a href="/wiki/Mosunetuzumab" title="Mosunetuzumab">Mosunetuzumab</a>), <i><a href="/wiki/CD20" title="CD20">CD20</a></i> (<a href="/wiki/Glofitamab" title="Glofitamab">Glofitamab</a></li> <li><a href="/wiki/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li> <li><a href="/wiki/Mosunetuzumab" title="Mosunetuzumab">Mosunetuzumab</a></li> <li><a href="/wiki/Obinutuzumab" title="Obinutuzumab">Obinutuzumab</a></li> <li><a href="/wiki/Ofatumumab" title="Ofatumumab">Ofatumumab</a></li> <li><a href="/wiki/Rituximab" title="Rituximab">Rituximab</a></li> <li><a href="/wiki/Tositumomab" title="Tositumomab">Tositumomab</a>), <i><a href="/wiki/CD30" title="CD30">CD30</a></i> (<a href="/wiki/Brentuximab_vedotin" title="Brentuximab vedotin">Brentuximab</a>), <i><a href="/wiki/CD52" title="CD52">CD52</a></i> (<a href="/wiki/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul> <ul><li><a href="/wiki/Myeloid" class="mw-redirect" title="Myeloid">myeloid</a>: <i><a href="/wiki/CD33" title="CD33">CD33</a></i> (<a href="/wiki/Gemtuzumab_ozogamicin" title="Gemtuzumab ozogamicin">Gemtuzumab ozogamicin</a>)</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Amivantamab" title="Amivantamab">Amivantamab</a></li> <li><a href="/wiki/Atezolizumab" title="Atezolizumab">Atezolizumab</a> (<a href="/wiki/Atezolizumab/hyaluronidase" title="Atezolizumab/hyaluronidase">+hyaluronidase</a>)</li> <li><a href="/wiki/Avelumab" title="Avelumab">Avelumab</a></li> <li><a href="/wiki/Axatilimab" title="Axatilimab">Axatilimab</a></li> <li><a href="/wiki/Belantamab_mafodotin" title="Belantamab mafodotin">Belantamab mafodotin</a></li> <li><a href="/wiki/Bermekimab" title="Bermekimab">Bermekimab</a></li> <li><a href="/wiki/Blinatumomab" title="Blinatumomab">Blinatumomab</a></li> <li><a href="/wiki/Cemiplimab" title="Cemiplimab">Cemiplimab</a></li> <li><a href="/wiki/Daratumumab" title="Daratumumab">Daratumumab</a></li> <li><a href="/wiki/Dinutuximab_beta" class="mw-redirect" title="Dinutuximab beta">Dinutuximab beta</a></li> <li><a href="/wiki/Dostarlimab" title="Dostarlimab">Dostarlimab</a></li> <li><a href="/wiki/Durvalumab" title="Durvalumab">Durvalumab</a></li> <li><a href="/wiki/Elotuzumab" title="Elotuzumab">Elotuzumab</a></li> <li><a href="/wiki/Enfortumab_vedotin" title="Enfortumab vedotin">Enfortumab vedotin</a></li> <li><a href="/wiki/Epcoritamab" title="Epcoritamab">Epcoritamab</a></li> <li><a href="/wiki/Inotuzumab_ozogamicin" title="Inotuzumab ozogamicin">Inotuzumab ozogamicin</a></li> <li><a href="/wiki/Ipilimumab" title="Ipilimumab">Ipilimumab</a></li> <li><a href="/wiki/Isatuximab" title="Isatuximab">Isatuximab</a></li> <li><a href="/wiki/Loncastuximab_tesirine" title="Loncastuximab tesirine">Loncastuximab tesirine</a></li> <li><a href="/wiki/Mirvetuximab_soravtansine" title="Mirvetuximab soravtansine">Mirvetuximab soravtansine</a></li> <li><a href="/wiki/Mogamulizumab" title="Mogamulizumab">Mogamulizumab</a></li> <li><a href="/wiki/Moxetumomab_pasudotox" title="Moxetumomab pasudotox">Moxetumomab pasudotox</a></li> <li><a href="/wiki/Naxitamab" title="Naxitamab">Naxitamab</a></li> <li><a href="/wiki/Necitumumab" title="Necitumumab">Necitumumab</a></li> <li><a href="/wiki/Nivolumab" title="Nivolumab">Nivolumab</a></li> <li><a href="/wiki/Olaratumab" title="Olaratumab">Olaratumab</a></li> <li><a href="/wiki/Oportuzumab_monatox" title="Oportuzumab monatox">Oportuzumab monatox</a></li> <li><a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a></li> <li><a href="/wiki/Polatuzumab_vedotin" title="Polatuzumab vedotin">Polatuzumab vedotin</a></li> <li><a href="/w/index.php?title=Prolgolimab&action=edit&redlink=1" class="new" title="Prolgolimab (page does not exist)">Prolgolimab</a></li> <li><a href="/wiki/Ramucirumab" title="Ramucirumab">Ramucirumab</a></li> <li><a href="/wiki/Retifanlimab" title="Retifanlimab">Retifanlimab</a></li> <li><a href="/w/index.php?title=Sabatolimab&action=edit&redlink=1" class="new" title="Sabatolimab (page does not exist)">Sabatolimab</a></li> <li><a href="/wiki/Sacituzumab_govitecan" title="Sacituzumab govitecan">Sacituzumab govitecan</a></li> <li><a href="/wiki/Serplulimab" title="Serplulimab">Serplulimab</a></li> <li><a href="/wiki/Sugemalimab" title="Sugemalimab">Sugemalimab</a></li> <li><a href="/wiki/Tafasitamab" title="Tafasitamab">Tafasitamab</a></li> <li><a href="/wiki/Talquetamab" title="Talquetamab">Talquetamab</a></li> <li><a href="/wiki/Tarlatamab" title="Tarlatamab">Tarlatamab</a></li> <li><a href="/wiki/Teclistamab" title="Teclistamab">Teclistamab</a></li> <li><a href="/wiki/Tislelizumab" title="Tislelizumab">Tislelizumab</a></li> <li><a href="/wiki/Tisotumab_vedotin" title="Tisotumab vedotin">Tisotumab vedotin</a></li> <li><a href="/wiki/Toripalimab" title="Toripalimab">Toripalimab</a></li> <li><a href="/wiki/Tremelimumab" title="Tremelimumab">Tremelimumab</a></li> <li><a href="/wiki/Zolbetuximab" title="Zolbetuximab">Zolbetuximab</a></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Tyrosine_kinase_inhibitor" title="Tyrosine kinase inhibitor">Tyrosine kinase inhibitors</a> ("-nib")</th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Receptor_tyrosine_kinase" title="Receptor tyrosine kinase">Receptor tyrosine kinase</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/ErbB" title="ErbB">ErbB</a>: <i><a href="/wiki/Epidermal_growth_factor_receptor" title="Epidermal growth factor receptor">HER1/EGFR</a></i> (<a href="/wiki/Afatinib" title="Afatinib">Afatinib</a></li> <li><a href="/wiki/Aumolertinib" title="Aumolertinib">Aumolertinib</a></li> <li><a href="/wiki/Brigatinib" title="Brigatinib">Brigatinib</a></li> <li><a href="/wiki/Dacomitinib" title="Dacomitinib">Dacomitinib</a></li> <li><a href="/wiki/Erlotinib" title="Erlotinib">Erlotinib</a></li> <li><a href="/wiki/Gefitinib" title="Gefitinib">Gefitinib</a></li> <li><a href="/wiki/Icotinib" title="Icotinib">Icotinib</a></li> <li><a href="/wiki/Lazertinib" title="Lazertinib">Lazertinib</a></li> <li><a href="/wiki/Mobocertinib" title="Mobocertinib">Mobocertinib</a></li> <li><a href="/wiki/Olmutinib" title="Olmutinib">Olmutinib</a></li> <li><a href="/wiki/Osimertinib" title="Osimertinib">Osimertinib</a></li> <li><a href="/wiki/Rociletinib" title="Rociletinib">Rociletinib</a></li> <li><a href="/wiki/Vandetanib" title="Vandetanib">Vandetanib</a>)</li></ul> <ul><li><i>HER1/EGFR and <a href="/wiki/HER2/neu" class="mw-redirect" title="HER2/neu">HER2/neu</a></i> <ul><li><a href="/wiki/Lapatinib" title="Lapatinib">Lapatinib</a></li> <li><a href="/wiki/Neratinib" title="Neratinib">Neratinib</a></li> <li><a href="/wiki/Tucatinib" title="Tucatinib">Tucatinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/BRAF_(gene)" title="BRAF (gene)">BRAF</a></i> <ul><li><a href="/wiki/Dabrafenib" title="Dabrafenib">Dabrafenib</a></li> <li><a href="/wiki/Encorafenib" title="Encorafenib">Encorafenib</a></li> <li><a href="/wiki/Vemurafenib" title="Vemurafenib">Vemurafenib</a></li></ul></li></ul> <ul><li><a href="/wiki/RTK_class_III" title="RTK class III">RTK class III</a>: <i><a href="/wiki/CD117" class="mw-redirect" title="CD117">C-kit</a> and <a href="/wiki/Platelet-derived_growth_factor_receptor" title="Platelet-derived growth factor receptor">PDGFR</a></i> (<a href="/wiki/Avapritinib" title="Avapritinib">Avapritinib</a></li> <li><a href="/wiki/Axitinib" title="Axitinib">Axitinib</a></li> <li><a href="/wiki/Masitinib" title="Masitinib">Masitinib</a></li> <li><a href="/wiki/Pazopanib" title="Pazopanib">Pazopanib</a></li> <li><a href="/wiki/Ripretinib" title="Ripretinib">Ripretinib</a></li> <li><a href="/wiki/Sorafenib" title="Sorafenib">Sorafenib</a></li> <li><a href="/wiki/Sunitinib" title="Sunitinib">Sunitinib</a></li> <li><a href="/wiki/Toceranib" title="Toceranib">Toceranib</a>)</li> <li><i><a href="/wiki/CD135" title="CD135">FLT3</a></i> (<a href="/wiki/Lestaurtinib" title="Lestaurtinib">Lestaurtinib</a>, <a href="/wiki/Gilteritinib" title="Gilteritinib">Gilteritinib</a> (AXL, ALK, LTK))</li></ul> <ul><li><i><a href="/wiki/VEGF_receptors" class="mw-redirect" title="VEGF receptors">VEGFR</a></i> <ul><li><a href="/wiki/Axitinib" title="Axitinib">Axitinib</a></li> <li><a href="/wiki/Cediranib" title="Cediranib">Cediranib</a></li> <li><a href="/wiki/Fruquintinib" title="Fruquintinib">Fruquintinib</a></li> <li><a href="/wiki/Lenvatinib" title="Lenvatinib">Lenvatinib</a></li> <li><a href="/wiki/Nintedanib" title="Nintedanib">Nintedanib</a></li> <li><a href="/wiki/Pazopanib" title="Pazopanib">Pazopanib</a></li> <li><a href="/wiki/Regorafenib" title="Regorafenib">Regorafenib</a></li> <li><a href="/wiki/Semaxanib" title="Semaxanib">Semaxanib</a></li> <li><a href="/wiki/Sorafenib" title="Sorafenib">Sorafenib</a></li> <li><a href="/wiki/Sunitinib" title="Sunitinib">Sunitinib</a></li> <li><a href="/wiki/Tivozanib" title="Tivozanib">Tivozanib</a></li> <li><a href="/wiki/Toceranib" title="Toceranib">Toceranib</a></li> <li><a href="/wiki/Vandetanib" title="Vandetanib">Vandetanib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Anaplastic_lymphoma_kinase" title="Anaplastic lymphoma kinase">ALK</a></i> <ul><li><a href="/wiki/Alectinib" title="Alectinib">Alectinib</a></li> <li><a href="/wiki/Brigatinib" title="Brigatinib">Brigatinib</a></li> <li><a href="/wiki/Ceritinib" title="Ceritinib">Ceritinib</a></li> <li><a href="/wiki/Crizotinib" title="Crizotinib">Crizotinib</a></li> <li><a href="/wiki/Lorlatinib" title="Lorlatinib">Lorlatinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/RET_proto-oncogene" title="RET proto-oncogene">RET</a> inhibitors:</i> <a href="/wiki/Entrectinib" title="Entrectinib">Entrectinib</a> (ALK, ROS1, NTRK), <a href="/wiki/Futibatinib" title="Futibatinib">Futibatinib</a> (FGFR2), <a href="/wiki/Infigratinib" title="Infigratinib">Infigratinib</a>, <a href="/wiki/Larotrectinib" title="Larotrectinib">Larotrectinib</a> (NTRK), <a href="/wiki/Pemigatinib" title="Pemigatinib">Pemigatinib</a> (FGFR), <a href="/wiki/Pralsetinib" title="Pralsetinib">Pralsetinib</a>, <a href="/wiki/Repotrectinib" title="Repotrectinib">Repotrectinib</a> (ROS1, TRK, ALK), <a href="/wiki/Selpercatinib" title="Selpercatinib">Selpercatinib</a> (VEGFR, FGFR), <a href="/wiki/Vandetanib" title="Vandetanib">Vandetanib</a> (VEGFR, EGFR).</li></ul> <ul><li><i><a href="/wiki/C-Met" class="mw-redirect" title="C-Met">c-MET</a> inhibitors:</i> <a href="/wiki/Cabozantinib" title="Cabozantinib">Cabozantinib</a> (VEGFR), <a href="/wiki/Capmatinib" title="Capmatinib">Capmatinib</a>, <a href="/wiki/Crizotinib" title="Crizotinib">Crizotinib</a> (ALK)</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Non-receptor_tyrosine_kinase" title="Non-receptor tyrosine kinase">Non-receptor</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><i><a href="/wiki/Bcr-abl_fusion_protein" class="mw-redirect" title="Bcr-abl fusion protein">bcr-abl</a></i> <ul><li><a href="/wiki/Asciminib" title="Asciminib">Asciminib</a></li> <li><a href="/wiki/Bosutinib" title="Bosutinib">Bosutinib</a></li> <li><a href="/wiki/Dasatinib" title="Dasatinib">Dasatinib</a></li> <li><a href="/wiki/Imatinib" title="Imatinib">Imatinib</a></li> <li><a href="/wiki/Nilotinib" title="Nilotinib">Nilotinib</a></li> <li><a href="/wiki/Ponatinib" title="Ponatinib">Ponatinib</a></li> <li><a href="/wiki/Radotinib" title="Radotinib">Radotinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Src_(gene)" class="mw-redirect" title="Src (gene)">Src</a></i> (<a href="/wiki/Bosutinib" title="Bosutinib">Bosutinib</a></li> <li><a href="/wiki/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul> <ul><li><i><a href="/wiki/Janus_kinase" title="Janus kinase">Janus kinase</a> (JAK)</i> <ul><li><a href="/wiki/Baricitinib" title="Baricitinib">Baricitinib</a></li> <li><a href="/wiki/Fedratinib" title="Fedratinib">Fedratinib</a></li> <li><a href="/wiki/Filgotinib" title="Filgotinib">Filgotinib</a></li> <li><a href="/wiki/Lestaurtinib" title="Lestaurtinib">Lestaurtinib</a></li> <li><a href="/wiki/Momelotinib" title="Momelotinib">Momelotinib</a></li> <li><a href="/wiki/Pacritinib" title="Pacritinib">Pacritinib</a></li> <li><a href="/wiki/Ruxolitinib" title="Ruxolitinib">Ruxolitinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Mitogen-activated_protein_kinase_kinase" title="Mitogen-activated protein kinase kinase">MAP2K</a> (MEK)</i> <ul><li><a href="/wiki/Binimetinib" title="Binimetinib">Binimetinib</a></li> <li><a href="/wiki/Cobimetinib" title="Cobimetinib">Cobimetinib</a></li> <li><a href="/wiki/Selumetinib" title="Selumetinib">Selumetinib</a></li> <li><a href="/wiki/Trametinib" title="Trametinib">Trametinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/EML4" title="EML4">EML4</a>-<a href="/wiki/Anaplastic_lymphoma_kinase" title="Anaplastic lymphoma kinase">ALK</a></i> <ul><li><a href="/wiki/Crizotinib" title="Crizotinib">Crizotinib</a></li> <li><a href="/wiki/Entrectinib" title="Entrectinib">Entrectinib</a></li> <li><a href="/wiki/Lorlatinib" title="Lorlatinib">Lorlatinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Bruton%27s_tyrosine_kinase" title="Bruton's tyrosine kinase">Bruton's</a> (BTK)</i> <ul><li><a href="/wiki/Acalabrutinib" title="Acalabrutinib">Acalabrutinib</a></li> <li><a href="/wiki/Ibrutinib" title="Ibrutinib">Ibrutinib</a></li> <li><a href="/wiki/Orelabrutinib" title="Orelabrutinib">Orelabrutinib</a></li> <li><a href="/wiki/Pirtobrutinib" title="Pirtobrutinib">Pirtobrutinib</a></li> <li><a href="/wiki/Zanubrutinib" title="Zanubrutinib">Zanubrutinib</a></li></ul></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><i><a href="/wiki/Fusion_protein" title="Fusion protein">fusion protein</a> against <a href="/wiki/Vascular_endothelial_growth_factor" title="Vascular endothelial growth factor">VEGF</a></i> (<a href="/wiki/Aflibercept" title="Aflibercept">Aflibercept</a>)</li></ul> <ul><li><i><a href="/wiki/Proapoptotic" class="mw-redirect" title="Proapoptotic">proapoptotic</a> peptide against <a href="/wiki/ANXA2" class="mw-redirect" title="ANXA2">ANXA2</a> and <a href="/wiki/Prohibitin" title="Prohibitin">prohibitin</a></i> (<a href="/wiki/Adipotide" class="mw-redirect" title="Adipotide">Adipotide</a>)</li></ul> <ul><li><i><a href="/wiki/Exotoxin" title="Exotoxin">exotoxin</a> against <a href="/wiki/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="/wiki/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li></ul> <ul><li><i><a href="/wiki/MTOR_inhibitor" class="mw-redirect" title="MTOR inhibitor">mTOR inhibitors</a></i> <ul><li><a href="/wiki/Everolimus" title="Everolimus">Everolimus</a></li> <li><a href="/wiki/Ridaforolimus" title="Ridaforolimus">Ridaforolimus</a></li> <li><a href="/wiki/Sirolimus" title="Sirolimus">Sirolimus</a></li> <li><a href="/wiki/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Hedgehog_signaling_pathway" title="Hedgehog signaling pathway">hedgehog</a> inhibitors</i> <ul><li><a href="/wiki/Glasdegib" title="Glasdegib">Glasdegib</a></li> <li><a href="/wiki/Sonidegib" title="Sonidegib">Sonidegib</a></li> <li><a href="/wiki/Vismodegib" title="Vismodegib">Vismodegib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/CDK_inhibitor" title="CDK inhibitor">CDK inhibitors</a></i> <ul><li><a href="/wiki/Abemaciclib" title="Abemaciclib">Abemaciclib</a></li> <li><a href="/wiki/Dalpiciclib" title="Dalpiciclib">Dalpiciclib</a></li> <li><a href="/wiki/Palbociclib" title="Palbociclib">Palbociclib</a></li> <li><a href="/wiki/Ribociclib" title="Ribociclib">Ribociclib</a></li> <li><a href="/wiki/Trilaciclib" title="Trilaciclib">Trilaciclib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/KRAS" title="KRAS">KRAS</a> inhibitors</i> <ul><li><a href="/wiki/Adagrasib" title="Adagrasib">Adagrasib</a></li> <li><a href="/wiki/Sotorasib" title="Sotorasib">Sotorasib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Pi3K_inhibitor" class="mw-redirect" title="Pi3K inhibitor">Pi3K inhibitors</a></i> <ul><li><a href="/wiki/Alpelisib" title="Alpelisib">Alpelisib</a></li> <li><a href="/wiki/Copanlisib" title="Copanlisib">Copanlisib</a></li> <li><a href="/wiki/Duvelisib" title="Duvelisib">Duvelisib</a></li> <li><a href="/wiki/Idelalisib" title="Idelalisib">Idelalisib</a></li> <li><a class="mw-selflink selflink">Inavolisib</a></li> <li><a href="/wiki/Parsaclisib" title="Parsaclisib">Parsaclisib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/MEN1" title="MEN1">Menin</a> inhibitors</i> <ul><li><a href="/wiki/Revumenib" title="Revumenib">Revumenib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Fibroblast_growth_factor_receptor" title="Fibroblast growth factor receptor">Fibroblast growth factor receptor</a></i> (FGFR) inhibitors</li> <li><a href="/wiki/Erdafitinib" title="Erdafitinib">Erdafitinib</a></li> <li><a href="/wiki/Futibatinib" title="Futibatinib">Futibatinib</a></li> <li><a href="/wiki/Infigratinib" title="Infigratinib">Infigratinib</a></li> <li><a href="/wiki/Pemigatinib" title="Pemigatinib">Pemigatinib</a></li></ul> <ul><li><a href="/wiki/Cabozantinib" title="Cabozantinib">Cabozantinib</a></li> <li><a href="/wiki/Capmatinib" title="Capmatinib">Capmatinib</a></li> <li><a href="/wiki/Entrectinib" title="Entrectinib">Entrectinib</a></li> <li><a href="/wiki/Gilteritinib" title="Gilteritinib">Gilteritinib</a></li> <li><a href="/wiki/Larotrectinib" title="Larotrectinib">Larotrectinib</a></li> <li><a href="/wiki/Lenvatinib" title="Lenvatinib">Lenvatinib</a></li> <li><a href="/wiki/Masitinib" title="Masitinib">Masitinib</a></li> <li><a href="/wiki/Midostaurin" title="Midostaurin">Midostaurin</a></li> <li><a href="/wiki/Nintedanib" title="Nintedanib">Nintedanib</a></li> <li><a href="/wiki/Odronextamab" title="Odronextamab">Odronextamab</a></li> <li><a href="/wiki/Pazopanib" title="Pazopanib">Pazopanib</a></li> <li><a href="/wiki/Pexidartinib" title="Pexidartinib">Pexidartinib</a></li> <li><a href="/wiki/Quizartinib" title="Quizartinib">Quizartinib</a></li> <li><a href="/wiki/Regorafenib" title="Regorafenib">Regorafenib</a></li> <li><a href="/wiki/Ripretinib" title="Ripretinib">Ripretinib</a></li> <li><a href="/wiki/Sorafenib" title="Sorafenib">Sorafenib</a></li> <li><a href="/wiki/Sunitinib" title="Sunitinib">Sunitinib</a></li> <li><a href="/wiki/Tebentafusp" title="Tebentafusp">Tebentafusp</a></li> <li><a href="/wiki/Tepotinib" title="Tepotinib">Tepotinib</a></li> <li><a href="/wiki/Vandetanib" title="Vandetanib">Vandetanib</a></li> <li><a href="/wiki/Venetoclax" title="Venetoclax">Venetoclax</a></li></ul> </div></td></tr></tbody></table></div> <style data-mw-deduplicate="TemplateStyles:r1130092004">.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-related{font-size:100%;justify-content:flex-start}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;flex:0 0 auto;min-height:24px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;flex:0 1 auto;padding:0.15em 0;column-gap:1em;align-items:baseline;margin:0;list-style:none}.mw-parser-output .portal-bar-content-related{margin:0;list-style:none}.mw-parser-output .portal-bar-item{display:inline-block;margin:0.15em 0.2em;min-height:24px;line-height:24px}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap;align-items:baseline}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-related{font-size:100%;align-items:flex-start}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:center;flex:0;column-gap:1em;border-top:1px solid #a2a9b1;margin:0 auto;list-style:none}.mw-parser-output .portal-bar-content-related{border-top:none;margin:0;list-style:none}}.mw-parser-output .navbox+link+.portal-bar,.mw-parser-output .navbox+style+.portal-bar,.mw-parser-output .navbox+link+.portal-bar-bordered,.mw-parser-output .navbox+style+.portal-bar-bordered,.mw-parser-output .sister-bar+link+.portal-bar,.mw-parser-output .sister-bar+style+.portal-bar,.mw-parser-output .portal-bar+.navbox-styles+.navbox,.mw-parser-output .portal-bar+.navbox-styles+.sister-bar{margin-top:-1px}</style><div class="portal-bar noprint metadata noviewer portal-bar-bordered" role="navigation" aria-label="Portals"><span class="portal-bar-header"><a href="/wiki/Wikipedia:Contents/Portals" title="Wikipedia:Contents/Portals">Portal</a>:</span><ul class="portal-bar-content"><li class="portal-bar-item"><span class="nowrap"><span typeof="mw:File"><span><img alt="icon" src="//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/8px-WHO_Rod.svg.png" decoding="async" width="8" height="19" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/12px-WHO_Rod.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/16px-WHO_Rod.svg.png 2x" data-file-width="107" data-file-height="250" /></span></span> </span><a href="/wiki/Portal:Medicine" title="Portal:Medicine">Medicine</a></li></ul></div>    </div><noscript><img src="https://login.wikimedia.org/wiki/Special:CentralAutoLogin/start?type=1x1&useformat=desktop" alt="" width="1" height="1" style="border: none; position: absolute;"></noscript> <div class="printfooter" data-nosnippet="">Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Inavolisib&oldid=1260343068">https://en.wikipedia.org/w/index.php?title=Inavolisib&oldid=1260343068</a>"</div></div> <div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Drugs_not_assigned_an_ATC_code" title="Category:Drugs not assigned an ATC code">Drugs not assigned an ATC code</a></li><li><a href="/wiki/Category:Antineoplastic_drugs" title="Category:Antineoplastic drugs">Antineoplastic drugs</a></li><li><a href="/wiki/Category:Phosphoinositide_3-kinase_inhibitors" title="Category:Phosphoinositide 3-kinase inhibitors">Phosphoinositide 3-kinase inhibitors</a></li><li><a href="/wiki/Category:Acetamides" title="Category:Acetamides">Acetamides</a></li><li><a href="/wiki/Category:Benzoxazepines" title="Category:Benzoxazepines">Benzoxazepines</a></li><li><a href="/wiki/Category:Difluoromethyl_compounds" title="Category:Difluoromethyl compounds">Difluoromethyl compounds</a></li><li><a href="/wiki/Category:Oxazolidinones" title="Category:Oxazolidinones">Oxazolidinones</a></li><li><a href="/wiki/Category:Drugs_developed_by_Genentech" title="Category:Drugs developed by Genentech">Drugs developed by Genentech</a></li><li><a href="/wiki/Category:Drugs_developed_by_Hoffmann-La_Roche" title="Category:Drugs developed by Hoffmann-La Roche">Drugs developed by Hoffmann-La Roche</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Source_attribution" title="Category:Source attribution">Source attribution</a></li><li><a href="/wiki/Category:Articles_with_short_description" title="Category:Articles with short description">Articles with short description</a></li><li><a href="/wiki/Category:Short_description_matches_Wikidata" title="Category:Short description matches Wikidata">Short description matches Wikidata</a></li><li><a href="/wiki/Category:Use_dmy_dates_from_November_2024" title="Category:Use dmy dates from November 2024">Use dmy dates from November 2024</a></li><li><a href="/wiki/Category:Articles_containing_unverified_chemical_infoboxes" title="Category:Articles containing unverified chemical infoboxes">Articles containing unverified chemical infoboxes</a></li><li><a href="/wiki/Category:All_articles_lacking_reliable_references" title="Category:All articles lacking reliable references">All articles lacking reliable references</a></li><li><a href="/wiki/Category:Articles_lacking_reliable_references_from_October_2024" title="Category:Articles lacking reliable references from October 2024">Articles lacking reliable references from October 2024</a></li></ul></div></div> </div> </main> </div> <div class="mw-footer-container"> <footer id="footer" class="mw-footer" > <ul id="footer-info"> <li id="footer-info-lastmod"> This page was last edited on 30 November 2024, at 06:19<span class="anonymous-show"> (UTC)</span>.</li> <li id="footer-info-copyright">Text is available under the <a href="/wiki/Wikipedia:Text_of_the_Creative_Commons_Attribution-ShareAlike_4.0_International_License" title="Wikipedia:Text of the Creative Commons Attribution-ShareAlike 4.0 International License">Creative Commons Attribution-ShareAlike 4.0 License</a>; additional terms may apply. By using this site, you agree to the <a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Terms_of_Use" class="extiw" title="foundation:Special:MyLanguage/Policy:Terms of Use">Terms of Use</a> and <a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Privacy_policy" class="extiw" title="foundation:Special:MyLanguage/Policy:Privacy policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a rel="nofollow" class="external text" href="https://wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li> </ul> <ul id="footer-places"> <li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Privacy_policy">Privacy policy</a></li> <li id="footer-places-about"><a href="/wiki/Wikipedia:About">About Wikipedia</a></li> <li id="footer-places-disclaimers"><a href="/wiki/Wikipedia:General_disclaimer">Disclaimers</a></li> <li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li> <li id="footer-places-wm-codeofconduct"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Universal_Code_of_Conduct">Code of Conduct</a></li> <li id="footer-places-developers"><a href="https://developer.wikimedia.org">Developers</a></li> <li id="footer-places-statslink"><a href="https://stats.wikimedia.org/#/en.wikipedia.org">Statistics</a></li> <li id="footer-places-cookiestatement"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Cookie_statement">Cookie statement</a></li> <li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Inavolisib&mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li> </ul> <ul id="footer-icons" class="noprint"> <li id="footer-copyrightico"><a href="https://wikimediafoundation.org/" class="cdx-button cdx-button--fake-button cdx-button--size-large cdx-button--fake-button--enabled"><img src="/static/images/footer/wikimedia-button.svg" width="84" height="29" alt="Wikimedia Foundation" loading="lazy"></a></li> <li id="footer-poweredbyico"><a href="https://www.mediawiki.org/" class="cdx-button cdx-button--fake-button cdx-button--size-large cdx-button--fake-button--enabled"><img src="/w/resources/assets/poweredby_mediawiki.svg" alt="Powered by MediaWiki" width="88" height="31" loading="lazy"></a></li> </ul> </footer> </div> </div> </div> <div class="vector-settings" id="p-dock-bottom"> <ul></ul> </div><script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgHostname":"mw-web.codfw.main-5c59558b9d-hrgxn","wgBackendResponseTime":151,"wgPageParseReport":{"limitreport":{"cputime":"0.648","walltime":"0.766","ppvisitednodes":{"value":5738,"limit":1000000},"postexpandincludesize":{"value":151337,"limit":2097152},"templateargumentsize":{"value":4814,"limit":2097152},"expansiondepth":{"value":19,"limit":100},"expensivefunctioncount":{"value":5,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":116188,"limit":5000000},"entityaccesscount":{"value":1,"limit":400},"timingprofile":["100.00% 671.714 1 -total"," 34.16% 229.475 1 Template:Infobox_drug"," 28.65% 192.436 1 Template:Reflist"," 26.66% 179.104 1 Template:Infobox"," 14.13% 94.934 11 Template:Cite_web"," 13.14% 88.237 3 Template:Navbox"," 12.91% 86.749 1 Template:Targeted_cancer_therapeutic_agents"," 9.30% 62.495 1 Template:Short_description"," 8.83% 59.329 12 Template:Cite_journal"," 6.47% 43.484 17 Template:Unbulleted_list"]},"scribunto":{"limitreport-timeusage":{"value":"0.371","limit":"10.000"},"limitreport-memusage":{"value":9016190,"limit":52428800}},"cachereport":{"origin":"mw-api-ext.codfw.main-74f675c4bb-gbs7n","timestamp":"20241130061913","ttl":2592000,"transientcontent":false}}});});</script> <script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"Article","name":"Inavolisib","url":"https:\/\/en.wikipedia.org\/wiki\/Inavolisib","sameAs":"http:\/\/www.wikidata.org\/entity\/Q122766610","mainEntity":"http:\/\/www.wikidata.org\/entity\/Q122766610","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https:\/\/www.wikimedia.org\/static\/images\/wmf-hor-googpub.png"}},"datePublished":"2023-03-19T14:05:10Z","dateModified":"2024-11-30T06:19:12Z","image":"https:\/\/upload.wikimedia.org\/wikipedia\/commons\/2\/28\/Inavolisib.svg","headline":"chemical compound"}</script> </body> </html>